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CHAPTER ONE:
Introduction to the Clostridium difficile Pathogen and Associated Diseases
Clostridium difficile (C. diff, Figure 1A) is a Gram-positive, anaerobic pathogen known
to form spores and give rise to hospital-acquired C. diff-associated diseases (CDAD).1 Often, the
infection is acquired by patient-to-patient transfer and subsequent ingestion of C. diff spores
known to survive in the hospital
setting.2, 3 CDAD is characterized by
a range of symptoms such as
excessive

diarrhea,

inflammation,

septic

colonic
shock,

pseudomembranous colitis (Figure
1C) and in extreme cases, death.1, 7
The cycle of CDAD manifestation
and recurrence is outlined in Figure
2. Essentially, patient treatment with
broad-spectrum

antibiotics

or

chemotherapeutic agents8 disturbs
	
  
Figure 1: C. diff pathogen and pseudomembranous colitis.
A: Scaled image of the Clostridium difficile microbe.4 B: Image
of a normal, healthy colon.5 C: Yellow plaques characteristic of
pseudomembranous colitis in a diseased patient.6

the normal bacterial community
within the colon, allowing C. diff to

	
  
colonize the gut and cause infection.7 Moreover, several antibiotic-resistant strains are
continually emerging, only some of which have been characterized.9,

10

These resistant,

hypervirulent strains, as well as the common production of environmentally-tolerant spores1, 3, 10
escalate relapse rates in previously treated patients.8 As a consequence of bacterial evolution,
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Figure 2: Cycle of CDAD manifestation and recurrence. Broad-spectrum antibiotics lead to the disruption
and modification of the normal microbiota in the gut, which subsequently allows C. diff to colonize. If the host
immune system is efficient enough to fight off the infection, then CDAD will be nullified. However, if the
immune system is compromised, C. diff will be allowed to release toxins, cause mucosal damage and
inflammation within the gut, and eventually evolve fully to CDAD. At this stage, the disease cycle is continued
via patient-to-patient transmission.11

	
  

	
  
prevalence and mortality rates associated with CDAD are actively increasing, with susceptibility
relying not only on antibiotic consumption and hospitalization, but elderly individuals and those
with inflammatory bowel disease (IBD) or human immunodeficiency virus (HIV) are also
especially vulnerable.12 Roughly 500,000 Americans per year acquire CDAD, where 1 out of
every 5 patients experience a recurrent infection, and nearly 30,000 of the overall infected
patients die within only one month of disease onset.13 Notably, 80% of yearly deaths due to C.
diff infection occurred among those aged 65 years and above.13 Furthermore, the number of
CDAD victims has recently outgrown those infected with methicillin-resistant Staphylococcus
aureus (MRSA), causing CDAD-related medical expenses to reach $4.8 billion in the United
States per year.13, 14
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Enterotoxins A (TcdA) and B (TcdB), shown in Figure 3, are the main virulence factors
produced by C. diff.10 Both TcdA/B are composed of four domains: an enzymatic
glucosyltransferase domain (GTD), a cysteine protease domain (CPD), a central translocation
domain (TD), and a receptor-binding region at the c-terminus, also known as the C-terminal
repetitive oligopeptide receptor-binding domain (CROP-RBD).15

The tcda and tcdb genes

encoding Toxin A and B, respectively, are located within a 19.6 kb chromosomal region known

Figure 3: Clostridium difficile’s primary virulence factors. The proteinaceous enterotoxins A (TcdA, top) and
B (TcdB, bottom) produced by C. diff are shown above with corresponding molecular weights to the left. Both
toxins are composed of four domains (GTD, red; CPD, blue; TD, orange; CROP-RBD, green) and differ mostly
in the length of their CROP-RBD regions. Each domain is labeled with the chronological number of amino acid
residues, beginning at the N-terminus. The recently determined crystal structure of the first three domains is
shown below (PDB: 4R04)16 as well as a segment of the TcdA CROP-RBD (PDB: 2F6E), which consists of 32
short repeats and 7 interspersed long repeats (light blue).17, 18	
  

	
  
as the pathogenicity locus (PaLoc).19 Also present within the PaLoc is tcdr and tcdc, which are
genes that code for a positive and a negative transcriptional regulator of toxin production,
respectively, and tcde, a holin-like protein necessary for secretion of the toxins into the
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surrounding environment. These three additional PaLoc genes, although extremely important, are
only a few of many factors involved in the regulatory networks of TcdA/B synthesis.19
Pathogenesis of TcdA/B is exceptionally fascinating; these holotoxins possess all
necessary machinery required to infect and kill cells. The mechanism of action (Figure 4),
although yet to be completely understood, proceeds by first utilizing the CROP-RBD to bind a
glycan receptor present at the surface of colonic epithelium cells.20 More specifically, the CROP

Figure 4: Mechanism of TcdA/B pathogenesis. A: Diagram of TcdA domains. B: Pathogenesis begins when
the CROP-RBD (green) binds a receptor and initiates endocytosis (1). As the endosomal pH drops, the TD
(orange) forms a pore-like structure that traverses the endosomal membrane. Next, the N-terminus translocates
into the cytosol (2), IP6 (black hexagons) causes self-cleavage of the CPD (blue) (3), and the GTD (red) is
released. Finally, the GTD enzymatically glucosylates Rho-GTPase proteins (purple) and causes cell death (4).21	
  

	
  
has portrayed specific binding affinity to glycan moieties ending in a Galα1,3Galβ1,4GlcNAc
sequence, where the α1,3 linkage amidst the two galactose sugars is suggested to be of
importance.22 Upon binding, receptor-mediated endocytosis is activated and results in an
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endosome-encapsulated toxin.23 The acidic environment, which is characteristic during
endosomal maturation, then allows the TD to unfold, expose its hydrophobic residues, and insert
into the endosomal membrane, forming a pore-like structure that acts as the pathway for
endosomal release.20, 24 Beginning at the N-terminus, the GTD and CPD are fed through the pore
and into the cytosol.24,

25

The mechanism of endosomal insertion and release is still not

completely known, but is believed to proceed in a way very similar to that of the anthrax toxin
produced by Bacillus anthracis.26 Upon entering the cytosol, the CPD binds native inositol
hexakisphosphate (IP6), which causes a conformational change allowing self-cleavage of the
CPD and release of the enzymatic GTD.24 The GTD is then free to exploit native UDP-glucose
(UDP-Glc) as a substrate by hydrolyzing UPD-Glc and transferring the glucose moiety to
threonine 37 of Rho GTPase family members (RhoA, Rac1, Cdc42) residing within intestinal
epithelium cells.27 Glycosylation of these small proteins (5-20 kDa) inactivates the enzymes
catalytic GTP-ase behavior, resulting in loss of tight junctions between cells, loss of intestinal
barrier function, cell death, and the characteristic symptoms of CDAD.8
The vigorous manifestation of C. diff and production of toxins also causes activation of
the host immune system.28, 29 As a first line of defense, the innate immune system generates nonspecific immunity by producing small proteins, called cytokines, which lead to numerous
downstream signaling events within the cell.30 Cytokines, such as interleukins and chemokines,
work together to identify and remove foreign matter by recruiting immune cells to the infection
site, balancing humoral and cell-based immunity, and activating the adaptive immune system.30,
31

A compromised immune system in combination with existing C. diff infection is unfavorable

and will likely progress illness within the patient, however an overactive immune system can
also be destructive by initiating an excessive inflammatory response that may damage healthy
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tissue. Therefore, although innate immunity is designed to fight off infection, when regarding C.
diff and CDAD patients, in fact the system most often produces a detrimental amount of colonic
inflammation that enhances disease progression.2, 32 Consequently, the problem and/or cure of
CDAD becomes two-fold; both host and pathogen play a synergistic role in C. diff disease
pathogenesis and progression.32 In other words, inhibition of bacterial colonization and toxic
virulence factors, as well as down-regulation of harmful inflammation in response to C. diff
bacterial components is needed to elicit an efficient therapeutic remedy.
A few of the current treatment methods to combat CDAD include antibiotic therapy, fecal
transplantation, probiotics, and immunotherapy.1,

33, 34

Antibiotics, such as vancomycin and

metronidazole, are usually the first course of action against the C. diff pathogen, however this
approach has shown to have high recurrence rates and is also responsible for numerous resistant
and hypervirulent strains.1 Probiotics and fecal transplantation are both methods that attempt to
reestablish the normal microflora within the gut, which is essential for diminishing C. diff and
curing the patient. Although probiotic and fecal transplantation therapies have had some success,
they both have downfalls as well. Probiotics, which are still considered to be controversial (not
always FDA regulated), are not typically potent enough to cure the infection on their own and
therefore are usually administered in conjunction with other treatments.33, 34 On the other hand,
fecal transplantation has had many good outcomes, however it is known to have low patient
compliance, moderate recurrence rates, and risk of transferring disease or other physiological
traits (obesity, depression, etc.) to the patient.1, 34, 35, 36
In attempt to sequester and fight off toxins, immunoglobulin and/or monoclonal
antibodies have had variable outcomes, however these therapies are often administered at
extremely high, sometimes toxic doses and again, usually in conjunction with other treatment
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methods.1, 33, 34 It would be ideal to avert the disease altogether, however there has yet to be a
preventative C. diff vaccine to pass clinical trials.1 With all things considered, the current
treatment options are ineffective and neglect to simultaneously target the bacterial pathogen and
the inflammation-causing virulence factors that have already been produced. Moving forward, an
effective therapeutic method that will inhibit all factors of CDAD is needed.
The specific goals of my thesis investigate GTD inhibition, host and pathogen
contribution to immune system activation, and production of active rTcdB-WT. To begin, the
first project deals with the development of an epoxide-containing peptide (HQS-Epoxy) as a
novel, covalent inhibitor of the glucosyltransferase activity of C. diff toxins A and B (Chapter
2). Here, I aim to elucidate the rate of relative inhibition and crosslinking of the epoxide inhibitor
to the GTD, the half-maximal inhibitory concentration (IC50) of the peptide, and visual
confirmation of cell protection against rTcdA-WT when inhibitor is present. Secondly, in regards
to the host immune system, a collaboration was formed with Dr. William Petri’s lab at the
University of Virginia to elucidate the relationship between C. diff bacteria/toxin exposure and
inflammasome activation within a murine host. Chapter 3 details in vitro and in vivo activation
of inflammation and cytokine production, as well as in vivo cellular damage, in response to
active rTcdA-WT. Finally, since toxin B was not yet available in the Feig Lab, Chapter 4
outlines the cloning, expression, and purification of rTcdB-WT and rTcdB-NVN (catalytically
inactive mutant), as well as in cellulo confirmation of rTcdB-WT cytotoxicity. Together, these
studies can facilitate characterization of CDAD as a whole, as well as distinguish the potential of
our peptide inhibitors, and give further insight to prospective therapeutic methods.

	
  

8	
  
CHAPTER TWO:
Irreversible Inhibition of Clostridium difficile Toxin A Glucosyltransferase Activity via an
Epoxide-Containing Peptide
As described in Chapter 1, both C. diff and the virulence factors TcdA/B are responsible
for activating the host innate immune system, initiating a detrimental inflammatory response, and
causing excessive damage to the colon.37, 38 Current treatment methods, most of which are
antibiotics that target C. diff, are only modestly effective at curing CDAD. As a result, methods
of targeting and inhibiting TcdA/B directly have become a topic of interest. Each of the four
domains of TcdA/B (GTD, CPD, TD, and CROP-RBD) play separate and significant roles
within the mechanism of infection, thus any of them can be targeted for inhibition.
With hopes of impeding initial CROP receptor-binding and entry of TcdA/B into host
cells, Cherian, et al., have recently engineered a cell line that stably expresses glycan derivatives
which can be used to identify potential therapeutics by determining specific, high-affinity glycan
receptor-binders.22 Studies have also identified specific regions within the TD that are imperative
for endosomal release of the toxin39 as well as molecules that disrupt pore formation and/or
translocation across the membrane, either structurally or by inhibiting endosomal acidification,
to culminate in an encapsulated toxin that is essentially nontoxic.40, 41 Furthermore, several
molecules have been reported to inhibit autoprocessing/cleavage of the CPD, activate premature
cleavage of the CPD (before entering host cell),42, 43, 44 and inhibit enzymatic activity of the
GTD,41, 45, 46 and although numerous attempts to obstruct TcdA/B on a molecular level have
revealed a better understanding of pathogenesis, none have led to a therapeutic antitoxin remedy
that is effective towards curing CDAD in humans.
Interested by the inherent and newly discovered inflammatory damage to the colon that is
the result of the GTD, the Feig Lab is currently investigating methods of TcdA/B
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Figure 5: Structure and production pathway of the HQS-Epoxy peptide inhibitor. The parent peptide
(HQS-Parent) is purchased with an allylglycine at the fifth position (red), a three-glycine linker (green) for
flexibility, and a cysteine residue for future labeling. Iodoacetamide is used to amidate and protect the Cterminal cysteine (blue) before treating with mCPBA to oxidize the allyl group to an epoxide at position five.

	
  
glucosyltransferase inhibition. Previously, Dr. Sanofar Abdeen used the phage display technique
to identify a heptapeptide (HQSPWHH) which exhibited nanomolar binding affinity to the GTD
of C. diff rTcdA.11, 46 Transitioning from phage to free peptide involved addition of a flexible
glycine linker and a C-terminal cysteine for future labeling and binding purposes, resulting in the
amino acid sequence HQSPWHHGGGC. As expected, this peptide displayed inhibition of
glucosyltransferase activity in vitro, however further studies unexpectedly showed that it lacked
the ability to protect against rTcdA in cellulo,11 which was hypothesized to be the result of
inhibitor dissociation during endosomal translocation.
To prevent dissociation and create a covalent connection between the inhibitor and the
GTD active site, the tryptophan at position 5 was replaced with allylglycine (HQS-Parent) and
subsequently modified to comprise a reactive epoxide moiety (HQS-Epoxy) with cross-linking
ability.11 The structure and derivatization process of HQS-Epoxy is depicted in Figure 5. Further
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analysis of HQS-Epoxy determined that incorporation of the epoxide did indeed generate an
irreversible inhibitor that was confirmed by mass spectrometry to cross-linked to the catalytic
region of rTcdA-GTD11, 47 and after incubation of 30 minutes successfully protected against
rTcdA in cellulo, demonstrating 95% cell protection at a concentration of 600 μM and a halfmaximal inhibitory concentration (IC50) of ~100 μM.11, 46 Kinetically, the binding of HQS-Epoxy
to rTcdA is a two step process that combines reversible and irreversible inhibition as described in
equation 1,
!+ 1

! + !   ⇌   !"

!!

!"*                                                     !". !

!− 1

that is partially competitive to UDP-Glc and RhoA substrates, where the inhibitory binding
affinity constant (KI) for the reversible, loosely bound EI complex is defined as k-1/k+1 and k2 is
the rate constant (i.e., cross-linking rate or rate of inactivation) corresponding to the tightly
bound, covalent EI* complex containing inactivated enzyme. Because of its potential to
dissociate (k-1), the initial EI complex formation is assumed to be a slower process than the
subsequent time-dependent EI* complex formation which is irreversible and results in a loss of
active enzyme over time.
To further analyze these kinetic parameters and extent of glucosyltransferase inhibition
generated by HQS-Epoxy, the optical coupled-enzyme assay displayed in Figure 6A was
employed. With UDP being a common product of both GH and GT enzymatic reactions
performed by rTcdA/B, this assay couples pyruvate kinase (PK) and lactate dehydrogenase
(LDH) to allow for the simultaneous detection of the individual rates by monitoring the
stoichiometric loss of NADH over time at an absorbance of 340 nm. Figure 6B depicts that
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when RhoA or a suitable GTPase is present, TcdA/B exploits both GH and GT functionality and
displays a rate that is the additive effect of both enzymatic reactions (kGH+GT). However, when

Figure
6:
The
coupled-enzyme
assay
simultaneously monitors glucosylhydrolase and
glucosyltransferase activity conferred by of
TcdA/B. A: UDP is the common product of both GH
and GT reactions. Pyruvate kinase (PK) and lactate
dehydrogenase (LDH) are coupled here, ultimately
leading to the oxidation of NADH, which is
monitored at A340 and stoichiometrically equivalent to
the amount of UDP consumed. B: The GTD of
TcdA/B acts on its UDP-Glc substrate in two specific
manners. In the absence of Rho-GTPases, UDP-Glc
is simply hydrolyzed, yielding separate UDP and
glucose molecules (glucosylhydrolase activity (kGH),
red). When s suitable accepter is present, UDP-Glc is
hydrolyzed and transferred, resulting in a UDP
molecule and an inactive, glucosylated GTPase
(glucosyltransferase activity (kGH+GT, purple).
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RhoA is not present or has been diminished, the resulting rate is that of the GH reaction (kGH)
alone, which can then be subtracted from kGH+GT to determine kGT. Pre-incubation of toxin with
various concentrations of HQS-Epoxy inhibitor, and for specified times prior to assay initiation,
was done to allow for a time-dependent analysis of GT inhibition and is discussed further below.
When using rTcdA-WT in the coupled-enzyme assay the slope of kGH+GT was determined
to be -6x10-5 μmol/min (1.85 turnovers/min), as seen in Figure 7A/B, which is hypothesized to
be the structural result of the holotoxin TD and CROP folding back and interacting with the GTD

Figure 7: kGH+GT rate of rTcdA-WT as determined by the coupled-enzyme assay and visual occlusion of
rTcdA-GTD at high pH. A: Initial NADH turnover rate of rTcdA-WT (1.85 turnovers/min) where the slope of
kGH+GT is -6x10-5 µmol NADH/min. B: Negative stain EM images reconstructed in 3D show structural changes
in rTcdA upon decreasing pH.48, 49 GTD: red. CPD: blue. TD: yellow. CROP-RBD: green.

and CPD in a manner that obstructs enzymatic activity prior to acidification and cleavage.16, 48, 49
Incubation of rTcdA-WT with IP6 has shown to induce cleavage and allow rTcdA-WT activity in
vitro,48 however this was not attempted for the coupled-enzyme assay to avoid adding another
enzymatic rate to the equation. Instead, in order to successfully analyze the GH and GT rates of
C. diff toxin A, the GTD was isolated as a truncated construct containing the first 540 amino
acids of the holotoxin (rTcdA540, Figure 8A).50, 51 As opposed to rTcdA-WT, rTcdA540 is fully
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Figure 8: Structure and distinct enzymatic rates of rTcdA540. A: Shown on top, rTcdA540 contains amino
acids 1-540 of the TcdA holotoxin producing a 66 kDa protein. Below, the structure of the GTD (PDB: 3SRZ)51
is displayed with catalytic residues D286 and D288 in green and UDP-Glc in blue. B: Example of data obtained
from the coupled-enzyme assay using rTcdA540, where kGH+GT is shown in purple with a slope of -0.00590
µmol/min (181.5 turnovers/min) and kGH is shown in red with a slope of -0.00046 µmol/min (14.2
turnovers/min).

	
  

active when used in the coupled-enzyme assay and gives distinct rates for GH and GT (Figure
8B), which have also been previously reported.11
Although analysis of rTcdA inhibition via HQS-Epoxy was monitored in cellulo,11, 46 the
overall extent of inhibition, crosslinking rate (k2), and additional kinetic parameters utilizing the
coupled-enzyme assay and rTcdA540 needed further investigation. Since the GH rate is slow and
minimally affected by HQS-Epoxy, an average GH rate of 15 ± 1 turnovers/min (n = 4) was
determined for rTcdA540 in the absence of inhibitor (data not shown). Once observed kGH+GT rates
in the absence and presence of varying HQS-Epoxy concentrations were determined, the average
GH rate of 15 ± 1 turnovers/min was subtracted to give the average initial GT turnover rates seen
in Figure 9A. At time zero, the GT rate of rTcdA540 (~140 turnovers/min) showed little change
regardless of inhibitor concentration, but continuous incubation of rTcdA540 with HQS-Epoxy at
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37 °C resulted in decreasing GT activity over time, indicating that the crosslinking process is not
occurring instantaneously and is in fact time-dependent. Figure 9A also shows that although
rTcdA540 lost roughly 50% activity over the 60 minute time course in absence of inhibitor, there
was nearly a 9.5 fold decrease in GT rate when in the presence of 600 μM inhibitor for the same

Figure 9: rTcdA540 glucosyltransferase rates for varying inhibitor concentrations over time. A: rTcdA540
(325 nM) was incubated with 0, 50, 100, 300 or 600 µM inhibitor at 37 °C for the duration of 1 hour. Aliquots
from each sample were taken at 0 (blue), 15 (red), 30 (green), and 60 min (purple) and added to the coupledenzyme assay to determine glucosyltransferase activity, shown here as inverse minutes. B: Relative rates (vi/vo)
for varying HQS-Epoxy concentrations (µM) at 0, 15, 30, and 60 minute time points. C: Percent inhibition of
300 µM (green) and 600 µM (purple) over time. All error bars indicate standard deviation; n = 3.
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time period. These data suggest that rTcdA540 loses enzymatic activity over the 60 minute time
course when incubated at 37 °C. However, this effect is not the sole reason for the decrease in
GT rate that is seen in presence of the inhibitor.
To account for loss of rTcdA540 activity over time, Figure 9B portrays the relative rate
(vi/vo) as a function of the corresponding pre-incubation time where vi is the GT rate in presence
of inhibitor, vo is the GT rate in absence of inhibitor, and vi equals vo when [inhibitor] = 0.
Representation of the kinetic data in this manner visually clarifies that 600 μM inhibitor results
in roughly 95% inhibition, agreeing with previously reported in cellulo data.11 Figure 9B also
exhibits that nearly 100% of potential crosslinking occurs in less than 15 minutes as longer
incubation times of 30 and 60 minutes did not confer additional inhibition, thus suggesting an
upper limit of 1.3 min-1 for the rate constant k2. Supplementary data at time points below 15
minutes are necessary to more accurately define the rate constant of the crosslinking event.
Nevertheless, IC50 values for the specified pre-incubation times were obtained by fitting
the data in Figure 9B to a generic half-life equation,
1
!! = !! ∙
2

!
!! !

                                                                   !". !

where Nt is the quantity remaining after time t, No is the initial quantity, and t1/2 is the half-life. In
this case however, when relative rates are plotted with inhibitor concentration on the x-axis, t1/2
then becomes the inhibitor concentration at 50% of the initial quantity, also known as the halfmaximal inhibitory concentration or IC50. Following Krippendorff, et. al.,52 to determine KI and
k2 variables, time-derived IC50 values were then graphed against time (Figure 9C) and fit by
non-linear least squares regression to equation 3,
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where IC50(t) is the half-maximal inhibitory concentration at time t, S is the substrate
concentration (RhoA), and KM is the Michaelis-Menten constant for RhoA.11, 50 All variables used
and/or derived from fitting the model equations 2 and 3 can be seen in Table 1.

Table 1: Kinetic variables for HQS-Epoxy inhibition of rTcdA 540.
Time-derived IC 50 Values (µM)

a

0 min

15 min

30 min

60 min

2487.7

409.4

357.6

355.2

S (µM) a

KM (µM) b

KI (µM)

k2 (min -1)

50

300

1066.5

1.3

RhoA substrate concentration used in assays. b Michaelis-Menten constant for RhoA affinity to TcdA11, 50

In comparison to previously reported values,11 the obtained KI of ~1100 μM is roughly
3.5 orders of magnitude larger than that found for HQS-Parent (KI = 300 nM) and one order
larger than the IC50 (100 μM) of HQS-Epoxy.11 An increase in the KI value was expected due to
decreased binding affinity of the modified peptide following addition of the epoxide moiety,
however it is also important to note that these values were obtained using different experimental
methods and fitting models. Furthermore, confirming that crosslinking was nearly complete by
the 15 minute time point (Figure 9B), combined with the lack of GT data corresponding to
critical time points below 15 minutes, the k2 value was somewhat expected to be inaccurate.
Presumably, the determined k2 of 1.3 min-1 is seemingly slow, reflecting an upper limit of this
value and indicating that EI* is formed at a constant rate of 1.3 crosslinking events per minute.
Again, this data is unable to be published because time points below 15 minutes are necessary to
accurately determine the values of KI and k2.
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To visualize if HQS-Epoxy confers cell protection against rTcdA at an incubation time
point of zero, toxin and inhibitor were mixed and immediately subjected to Vero cells for 1 hour
before imaging. Contrary to the GT kinetics reported above, Figure 10 shows that even with
zero pre-incubation time allotted for crosslinking, the majority of cells were alive and protected
from the rounding effects of rTcdA, but in the absence of HQS-Epoxy, cells containing 0.2 nM
rTcdA were severely disrupted and nearing death after only 1 hour. These data verify the fact
that HQS-Epoxy crosslinks to the GTD in less than 15 minutes and most likely does so following
CROP-receptor binding and endosomal acidification, as the TD and CROP interact with the
GTD prior to these events,16, 48, 49 which was corroborated by the lack of activity for rTcdA-WT in
the coupled-enzyme assay. Moreover, incubation of Vero cells with 600 μM HQS-Epoxy alone
determined that the epoxide-containing peptide inhibitor is in fact not toxic to cells and further
validates its potential use as an antitoxin therapeutic.

	
  
Figure 10: Visual cell protection against rTcdA in presence of HQS-Epoxy inhibitor. Vero cells were
grown to confluency at 37 °C and 5% CO2 and images were taken at time zero (top row) before addition of 0.2
nM rTcdA-WT (column 2), 0.2 nM rTcdA-WT and 600 µM inhibitor (column 3; no preliminary incubation time
allotted), or 600 µM inhibitor alone (column 4). Cells were then incubated at 37 °C and 5% CO2 for 1 hour
before imaging again (bottom row). After 1 hour, cells in column 1 (control; media only) show no change as
expected. Cells in column 4 remain flat and adherent, indicating that 600 µM inhibitor does not seem to harm
cell viability. Following incubation with 0.2 nM rTcdA-WT, Vero cells are rounded, detaching from surface,
and showing signs of cell death, however, majority of Vero cells are protected and remain adherent with
addition of inhibitor.
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The contrast of in vitro and in cellulo inhibitor effects at time zero are not extremely
surprising, however; since the inhibitor peptide cannot bind rTcdA-WT before receptor binding
and/or conformational change from endosomal acidification, there is an intrinsic delay in EI and
EI* complex formation that may account for this phenomenon. Further, the pH dependence on
crosslinking rate (k2) has yet to be determined. It may initially be assumed that alkaline pH
values will have an additive effect on k2 by increasing the nucleophilicity of the amino acid that
crosslinks to the active site,11 but it can also be suggested that low pH may result in protonation
of the epoxide moiety thereby increasing the electrophilic nature and enhancing k2 as well.
Future GT inhibition studies with varying pH will be useful in determining the pH-dependent
effects on KI and k2. Lastly, it is known11 that HQS-Epoxy is somewhat competitive in respect to
UDP-Glc and RhoA, the concentrations of which are higher than that of biological environments
during the in vitro assay, and may also confer inhibition of HQS-Epoxy binding to some extent.
Future analysis of HQS-Epoxy in vivo, potentially within a mouse model, is needed to
determine extent of inhibition, toxicity levels, stability of the peptide, and persistence of
inhibitory impact when in a biological environment. Moreover, since HQS-Epoxy portrays a
binding affinity and IC50 within the high μM range, a future reselection process to identify a
mimicking peptide with nM affinity may be beneficial. Determining more accurate values for KI
and k2 between 0 and 15 minutes, as well as the pH-dependence imposed on these variables, will
also further characterize the epoxide-containing peptide and in doing so, these studies will help
dictate the potential of HQS-Epoxy as a therapeutic agent to combat CDAD.
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CHAPTER TWO METHODS
B. meg protoplast generation. All procedures containing B. meg were carried out in a
Biosafety Level 2 (BL2) lab following standard operating procedures. B. meg cells were grown
overnight in 5 mL Difco™ Antibiotic Medium 3 (AB3) at 37 °C and 250 rpm. Fresh, warmed
AB3 medium (50 mL) was then inoculated with 1 mL of overnight culture and incubated at 37
°C and 250 rpm until an A550 of 1.0 was reached. Cells were harvested (2000 rpm, 10 min,
ambient temp), resuspended in 5 mL SMMP (1:1 AB3/SMM (40 mM maleic acid, 80 mM
NaOH, 40 mM MgCl2, 1 M sucrose)), and transferred to a 100 mL flask before adding 2 mg/mL
lysozyme and incubating (37 °C, 100 rpm, 45-60 min). Again, cells were harvested (2250 rpm,
10 min, ambient temp), washed with 5 mL SMMP, and harvested once more as before. Finally,
cells were resuspended in 5 mL SMMP (containing 10% (w/v) glycerol) and aliquoted before
storing at -80 °C. Protoplasts were visualized by phase-contrast microscopy.
B. meg plasmid transformation. B. meg protoplasts (200 μL) were thawed and 0.5-1 μg
of E. coli miniprepped-plasmid DNA was added, followed by addition of 600 μL PEG-P (40%
(w/v) PEG6000, 500 mM sucrose, 20 mM sodium maleinate, 20 mM MgCl2, pH 6.5) solution
was inverted to mix. Cells were incubated on ice and then at room temperature for 2 min each,
followed by addition of 2 mL SMMP, gentle inversion, and harvesting (3000 rpm, 10 min,
ambient temp). Supernatant was removed and 500 μL fresh SMMP was added before outgrowing
at 37 °C and 100 rpm for 90 min. Transformed culture was finally mixed with topagar, plated
(LB agar plus 10 μg/mL tetracycline (tet)), and incubated at 37 °C for 16 hours. Colonies were
restreaked on tet plates to ensure selection.
rTcdA/B protein expression and purification. B. meg cells containing the rTcdA/B
plasmid were first grown overnight (37 °C, 250 rpm, 16-19 hours) in 10 mL LB containing 10
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μg/mL tet before inoculating 1 L LB flasks (10 μg/mL tet) with the 10 mL overnight culture.
Cells were then grown to OD600 of 0.4, induced by addition of 0.5% D-xylose, and incubated to
OD600 of 1.5. Cells were harvested (8500g, 10 min, 4 °C) and stored at -80 °C until use. Thawed
cell pellets (1-2 L) containing lysis buffer (50 mM Na2HPO4, 300 mM NaCl, 10 mM imidazole,
pH 8) and protease inhibitors were lysed by sonication (5 cycles at 37% power) and centrifuged
to clarify (15,000 rpm, 45 min, 4 °C). Supernatant was filtered through 0.8 μm and 0.22 μm
syringe filters, respectively, before removing from BL2 constraint. Crude lysate was purified
first via nickel affinity column chromatography, followed by size exclusion column
chromatography and a second affinity column to concentrate the protein. Affinity columns were
washed with increasing concentrations of imidazole and elution was achieved with 250 mM
imidazole. Lysates were filtered through 0.22 μm filters after each chromatography step and
preceding dialysis (10,000 MWCO) into storage buffer (50 mM HEPES-K, 100 mM KCl, 1 mM
MgCl2, pH 7.5).
rTcdA540 protein expression and purification. BL21 DE3 E. coli cells containing the
rTcdA540 plasmid (pNLA 20405;50 transformed via electroporation) were first grown overnight
(37 °C, 250 rpm, 16-19 hours) in 10 mL LB containing 10 μg/mL amp and 34 μg/mL cam before
inoculating 1 L LB flasks (10 μg/mL amp and 34 μg/mL cam) with the 10 mL overnight culture.
Cells were then grown to OD600 of 0.4-0.6, induced by addition of 1 mM IPTG, and expressed 45 hours. Cells were harvested (5500g, 10 min, 4 °C) and stored at -80 °C until use. Thawed cell
pellets (1-3 L) containing lysis buffer (50 mM Na2HPO4, 300 mM NaCl, 10 mM imidazole, pH
8) and protease inhibitors were lysed by sonication (5 cycles at 37% power) and centrifuged to
clarify (10,000 rpm, 45-60 min, 4 °C). Supernatant was filtered through 0.8 μm and 0.45 μm
syringe filters, respectively, before removing from BL2 constraint. Crude lysate was purified
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first via nickel affinity column chromatography, followed by size exclusion column
chromatography and a second affinity column to concentrate the protein. Affinity columns were
washed with increasing concentrations of imidazole and elution was achieved with 250 mM
imidazole. Lysates were filtered through 0.22 μm syringe filters after each chromatography step
and preceding dialysis (10,000 MWCO) into storage buffer (50 mM HEPES-K, 100 mM KCl, 1
mM MgCl2, pH 7.5).
RhoA GTPase expression and purification. Rosetta 2 (DE3) E. coli cells containing the
RhoA-v4 plasmid (pNLA 20504;50 transformed via electroporation) were first grown overnight
(37 °C, 250 rpm, 16-19 hours) in 10 mL LB containing 30 μg/mL kan and 34 μg/mL cam before
inoculating 1 L LB flasks (30 μg/mL kan and 34 μg/mL cam) with the 10 mL overnight culture.
Cells were then grown to OD600 of 0.4-0.6, induced by addition of 1 mM IPTG, and expressed 45 hours. Cells were harvested (5500g, 10 min, 4 °C) and stored at -80 °C until use. Thawed cell
pellets (1-3 L) containing lysis buffer (50 mM HEPES, 300 mM NaCl, 1 mM MgCl2, pH 8) and
protease inhibitors were lysed by sonication (5 cycles at 37% power) and centrifuged to clarify
(10,000 rpm, 45-60 min, 4 °C). Supernatant was filtered through 0.8 μm and 0.2 μm syringe
filters, respectively. Crude lysate was purified via nickel affinity column chromatography,
washed with increasing concentrations of imidazole, and eluted with 150 mM imidazole.
Lysates were filtered through a 0.22 μm syringe filter preceding dialysis (3500 MWCO) into
storage buffer (50 mM HEPES-K, 100 mM KCl, 1 mM MgCl2, pH 7.5). Protein was
concentrated (3500 MWCO) if necessary.
Optical coupled-enzyme assay. Reactions contained 50 μM RhoA, 0.5 mM UDPGlucose, 35 units/mL pyruvate kinase, 75 units/mL lactate dehydrogenase, 1 mM PEP, and 0.2
mM NADH in storage buffer (50 mM HEPES-K, 100 mM KCl, 1 mM MgCl2, pH 7.5). Toxin
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(rTcdA540 or rTcdA-WT) at concentrations ranging from 32.5-325 nM, with or without inhibitor
present, was added to initiate the reaction (100 μL final volume) at 0, 15, 30 and 60 min time
points, and the decline of A340 was monitored using an Agilent 8453 UV-VIS spectrophotometer
equipped with a circulating water bath set to 37 °C. For inhibition studies, 50, 100, 300, or 600
uM HQS-Epoxy inhibitor peptide was used. Reactions were incubated at 37 °C over the duration
of the experiment.
HQSPGallylHHGGGC-NH2 peptide protection, epoxidation and purification.

11

HQSPGallylHHGGGC-NH2 (HQS-Parent) was purchased from American Peptide, resuspended to
a final concentration of 1 mg/mL in 20% ACN/H20, and purified by reverse-phase highperformance liquid chromatography (RP-HPLC) using a semi-preparative C-18 column (5-65%
linear gradient of 0.1% TFA/ACN, flow 1.00 ml/min). Peptide fractions were collected, flashfroze via liquid nitrogen, and lyophilized overnight. A 1:1 molar ratio of dried HQS-Parent
peptide and DTT was dissolved in 0.1 M (NH4)2CO3 buffer pH 8, flushed with N2 and incubated
at 54 °C for 30 min. Next, solid iodoacetamide was added in 10-fold molar excess. Reaction was
kept under N2 in the dark, with continuous stirring for 2 hours, and then purified by RP-HPLC
and lyophilized as above. Keeping under N2, dried HQS-Protected peptide and 10-fold molar
excess m-chloroperoxybenzoic acid (mCPBA) was added to a stirred solution of 2:1 CH2Cl2:0.01
M Na2HPO4/NaH2PO4 buffer pH 8, and incubated at room temperature with continuous stirring
for at least 5 hours. Reaction progress was monitored by thin-layer chromatography (mobile
phase 7:2:1 NH4OH: H20: 2-propanol). Peptide was precipitated and washed 6 times by addition
of diethyl ether to the aqueous layer. Peptide was then lyophilized, redissolved in water, and
desalted by addition of ACN (50% v/v), centrifugation (4 °C, 10,000g, 10 min), and removal of
supernatant from salt pellet. Again, peptide was purified as above, lyophilized, and stored at -20
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°C until use. Mass spectrometry after each step determined presence of peptide.
Vero cell cultures. All procedures containing Vero cells were carried out in a Biosafety
Level 2 (BL2) lab following standard operating procedures. Vero cell glycerol stocks were
removed from -80 °C and quickly (less than 1 min) warmed to 37 °C in a water bath. Cells were
suspended in 6 mL warm Eagle’s Minimum Essential Media (EMEM) enriched with 10% fetal
bovine serum (FBS) and 1% Antibiotic-Antimycotic (Anti-Anti) and spun down (200g, 5 min,
ambient temp). Media was removed from pellet and cells were resuspended in 3 mL fresh media,
which was plated in a 25 mL culture flask and incubated at 37 °C and 5 % CO2. Once grown to
roughly 80% confluency, adherent cells were passaged and regenerated as followed: EMEM was
removed and 0.5 mg/mL trypsin was added before incubating the flasks at 37 °C and 5% CO2 for
3 minutes or less. Trypsinized cells were then diluted 3X with EMEM, harvested (200g, 5 min,
ambient temp), resuspended with 5 mL EMEM and new culture flasks were seeded with 50 μL
resuspended cells and 3 mL fresh EMEM before incubating as before. Newly plated cells from
glycerol stocks underwent a minimum of three passages before being used in any experiments.
Visual cell protection assay. Vero cells were seeded in a clear, 12-well plate in 500 μL
Eagle’s Minimum Essential Media (EMEM) enriched with 10% fetal bovine serum (FBS) and
1% Antibiotic-Antimycotic (Anti-Anti), incubated at 37 °C and 5 % CO2, and grown to roughly
80% confluency. Wells were imaged using a Nikon Eclipse TS100 (Nikon Intensilight C-HGFI)
and washed twice with 1 mL serum-free EMEM (SF-EMEM supplemented with 1% Anti-Anti)
before adding either SF-EMEM alone, 0.2 nM rTcdA-WT, 0.2 nM rTcdA-WT plus 600 μM
HQS-Epoxy peptide inhibitor, or 600 μM HQS-Epoxy peptide inhibitor topped off with SFEMEM to a final volume of 500 μL. Cells were then incubated (37 °C, 5 % CO2) for 1 hour
before imaging again.
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CHAPTER THREE:
Glucosylation Drives the Innate Inflammatory Response to Clostridium difficile Toxin A38
In effort to further understand the role of immune system activation in CDAD, the Feig
Lab collaborated with the Petri Lab in the Immunology Department at the University of Virginia.
The Petri Lab has recently reported evidence of elevated levels of specific proinflammatory
cytokines (IL-23 and IL-1β) that enhance disease progression in specimens positive for C. diff
infection.37,

53

Furthermore, Cowardin, et al., allude to the fact that activation of a robust

inflammatory response is the result of not only C. diff toxins, but also the presence of a necessary
precursor, or “priming” signal, brought on by bacterial components known as pathogenassociated molecular patterns (PAMPs).37 Since part one of my thesis project deals solely with
inhibition of GTD, the recent discoveries from the Petri Lab are of particular interest to me, not
to mention the fact that they have access to mouse models. Moreover, the experiments in the
Petri Lab, until now, were done with naturally isolated C. diff toxins, but that precludes the use
of modified and mutant toxins, which provide a more granular probe of toxin activity. With the
Feig Lab’s background in biochemistry, the Petri Lab’s knowledge of immunology, and the
common interest of CDAD, a collaborative partnership was formed. Goals of this collaboration
included further mechanistic understanding of inflammasome activation upon C. diff exposure,
specific pathways involved in inflammation upregulation, and specific players associated with
these pathways, which can be seen in Figure 11.
A previous lab member, Dr. Amy Kerzmann, genetically modified wild type rTcdA by
site-directed mutagenesis to produce an enzymatically-inactive mutant, named rTcdA-NVN,
with commonly known D285N and D287N mutations.50, 54 To begin collaboration with Carrie
Cowardin in the Petri Lab, expression plasmids containing these genes (rTcdA-WT,
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pANK_80406; rTcdA-NVN, pANK_80407) were transformed into Bacillus megaterium (B.
meg), expressed, and purified before shipping to the University of Virginia. Final SDS-PAGE
gels depicting the purity of these proteins are shown in Figure 12A. The final elution fraction
(E*) containing the toxins also shows the presence of a protein band just below rTcdA that was
unable to be resolved and separated with the size-exclusion column in our lab due to very similar
molecular weights. Also existing in the E* lane is a band below 72 kDa, which was previously
identified by mass spectrometry11 to be the 63 kDa GTD that is produced by self-cleavage of
rTcdA at the CPD. The higher molecular weight positioning on the gel is most likely due to
different charge distribution within the molecules. Although not yet tested by mass spectrometry,
it would seem apparent then that the small band above 170 kDa and below rTcdA is likely rTcdA
with the loss of GTD (roughly 245 kDa) after self-cleavage.

Figure 11: Overview and key components of C. diff immune system activation pathways. C. diff PAMPs
and toxins produced after colonization activate the host innate immune system by initiating cytokine production
and recruiting immune cells (macrophages, mast cells, monocytes, etc.) to the site of infection. Immune cells
subsequently express more cytokines, creating a positive feedback loop. The proinflammatory cytokines IL-6
and pro-IL-1β are produced mainly by monocytes; IL-6 results in the recruitment of other immune cells (B
cells, T cells, natural killer (NK) cells, and neutrophils) while pro-IL-1β becomes IL-1β after caspase 1
cleavage.55, 56 IL-1β then binds to dendritic cell surface toll-like receptors (TLR) where it initiates expression of
the NF-κB protein complex, a transcriptional regulator, which in turn upregulates proinflammatory cytokines,
such as CXCL1.57, 58, 59
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rTcdA-WT and NVN mutant were assayed for activity by the CellTiter-Glo®
Luminescent Cell Viability Assay.60 Data in Figure 12B shows decreasing ATP concentrations
(shown as relative light units; RLU) in the presence of increasing rTcdA-WT, indicating
functional glucosyltransferase activity and loss of cell viability, where the cell population was
killed with a half-maximal inhibitory
concentration (IC50) near 0.7 nM. Cell
viability

is

also

reduced

with

increasing rTcdA-NVN, however cell
death is significantly less than that
seen for rTcdA-WT treatment, and is
most likely due to toxicity from leaky
endosomes since pore formation is still
occurring. Furthermore, increasing the
concentration of toxin results in less
	
  
	
  
Figure 12: Purity and activity of rTcdA-WT and rTcdANVN. A: SDS-PAGE gels after purification of rTcdA-WT
(left) and NVN (right). M: protein marker, F: column
flowthrough, B: wash fraction (20 mM imidazole), W: wash
fraction (50 mM imidazole), E1: first elution fraction (0.5 mL,
250 mM imidazole), E*: pooled elution fractions containing
rTcdA (2.5 mL). Protein marker molecular weights are shown
to the left and the arrows indicates the self-cleavage products.
B: Graph of cell viability data after incubation with toxins.
RLU: relative light units. Blue diamonds: rTcdA-WT; red
squares: rTcdA-NVN; green triangles: cells with no toxin;
purple crosses: media background with no cells. n = 9.

volume of media per well, which may
also contribute to cell death. Although
utilization of a wider concentration
range of these toxins would have
yielded more valuable data in Figure
12B, a visual verification of rTcdA-

	
  
WT activity can also be seen in Figure 13. Phase-contrast microscopy displays rounding of
HeLa cells after a 24-hour incubation period with 0.2 nM rTcdA-WT, indicating apoptosis and
cell death.
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Using

these

recombinant toxins in Dr.
Bill Petri’s lab, in vitro
experiments done by Dr.
Carrie

Cowardin38

murine

bone

derived

dendritic

(mBMDCs)
	
  
Figure 13: Phase-contrast microscopy images of rTcdA-WT-treated
HeLa cells. HeLa cells incubated with 0.2 nM rTcdA-WT (right) were
imaged before (top) and after 24 hours (bottom). Control cells (left) were not
treated with toxin.
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THP-1 monocytes (hTHP1)37 indicated significantly
elevated levels of CXCL1,

IL-6, IL-1β, and caspase 1 after incubation with rTcdA-WT in comparison to NVN and controls
(Figure 14A-B). CXCL1, also known as growth-related oncogene alpha or chemokine (C-X-C
motif) ligand 1, is a chemokine (i.e., chemotactic cytokine) that uses methods of chemotaxis to
recruit leukocytes to the site of inflammation and infection.57 IL-1β and IL-6, cytokines
predominantly produced by monocytes, promote damaging inflammation via cellular infiltration.
IL-1β is responsible for the induction of IL-6, as well as many other cytokines, and is even
involved in a positive feedback loop for its own upregulation. IL-1β’s major contribution to
inflammation comes from activation of the arachidonate/eicosanoid metabolism. Although IL-1β
and IL-6 share many biological roles, IL-6 is further involved in stimulating B-lymphocyte
maturation and T-cell regulation, particularly the differentiation of T-cells into cytotoxic Tcells.55 Caspase 1, also named interleukin-1 converting enzyme (ICE), is responsible for the
proteolytic cleavage of pro-IL-1β to its active IL-1β form.56 Figure 14B exhibits increased levels
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Figure 14: rTcdA-WT activates inflammasome and cytokine production in vitro. mBMDCs (A) and hTHP1 monocytes (B) were incubated with indicated concentrations of rTcdA toxins plus or minus LPS priming.
Lysates were analyzed by ELISA for protein production after 24 hours. C: Murine RAW-Blue macrophages
were subject to displayed rTcdA concentrations. SEAP levels reporting NF-κB activation were quantified in the
culture media by the QUANTI-Blue assay at 24 hours.38

of caspase 1, indicating a systemic inflammatory response upstream of IL-1β. Moreover, the
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway, which is a
blueprint of proinflammatory signaling, shows to be significantly triggered in the presence of
rTcdA-WT (Figure 14C). Activated by cytokines, such as IL-1 and TNFα, this pathway
involves several proteins acting as regulatory transcriptional factors for genes encoding
proinflammatory cytokines, chemokines, and adhesion molecules, including CXCL1 mentioned
above.58, 59 These data (recently published)38 indicate that glucosyltransferase activity is needed to
induce such inflammatory responses, and in the case of caspase 1 and IL-1β, a priming signal is
needed as well.
Also done in the Petri Lab by Dr. Carrie Cowardin,38 injections of rTcdA toxin were
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Figure 15: rTcdA-WT initiates
cytokine production in vivo. Indicated
toxin (15 µg) was injected into the
cecum of mice. After 8 hours, mice were
sacrificed and cecal tissue lysates were
analyzed for cytokine levels by ELISA.
Each data point represents an individual
mouse.38

	
  

Figure 16: Histology report of mice cecal sections in
response to C. diff rTcdA. Murine cecal sections were
analyzed by hematoxylin-eosin staining after treatment with
WT-rTcdA (top right) or NVN-rTcdA (bottom left). Control
mice (Mock; top left) were not subject to either toxin.
Quantitation of tissue damage for each group of mice is shown
in the bottom right, where each data point represents one
individual mouse (n = 8/group).38

placed into the cecum of mice by laparotomy and
subsequently subjected to cecal tissue analysis. Figure 15
demonstrates the escalated appearance of cytokines

(CXCL1, IL-1β, and IL-6) determined by ELISA, within the in vivo surroundings of the mouse
colon. The destruction caused by rTcdA-WT and said proinflammatory cytokines can be
visualized in Figure 16. Mice injected with rTcdA-WT show a significantly disrupted epithelial
barrier in comparison to rTcdA-NVN and controls.
The growing issue and prevalence of CDAD has shown to be more complicated than
previously known. Not only does the C. diff pathogen play a major role in the disease, but recent
evidence also shows the host immune system is partially to blame.32, 37, 53 These data demonstrate
that the host immune system binds to and recognizes C. diff PAMPs as part of the priming
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process. However glucosylation of cellular targets by rTcdA is necessary to induce significant
inflammation and cytokine production.38 These results further our understanding of how the C.
diff glucosylating toxins and the host immune system act in concert to mediate CDAD colitis.
The outcomes lend support to the ongoing development of toxin inhibitors, as this work shows
that if delivered and dosed correctly, inhibited toxins would not activate the immune system in a
manner that would damage the colon. This would also provide time for the patient to complete
their course of primary antibiotics and undergo fecal transplantation to restore the gut
microbiome to its initial state prior to the antibiotic therapy that allowed C. diff to colonize the
patient’s GI tract.

CHAPTER THREE METHODS
HeLa cell cultures. All procedures containing HeLa cells were carried out in a Biosafety
Level 2 (BL2) lab following standard operating procedures. HeLa cells were initially obtained
from the Pflum Lab at Wayne State University. Cells were grown in 25 mL culture flasks
containing Eagle’s Minimum Essential Media (EMEM) enriched with 10% fetal bovine serum
(FBS) and 1% Antibiotic-Antimycotic (Anti-Anti) and incubated at 37 °C and 5 % CO2. Once
grown to roughly 80% confluency, adherent cells were passaged and regenerated as followed:
EMEM was removed and 0.5 mg/mL trypsin was added before incubating the flasks at 37 °C and
5% CO2 for 3 minutes. Trypsinized cells were then diluted 3X with EMEM and harvested
(1000g, 7 min, ambient temp). Cells were resuspended with 5 mL EMEM and new culture flasks
were seeded with 50 μL resuspended cells and 3 mL fresh EMEM before incubating as before.
Luminescent cell viability assay. CellTiter-Glo® luminescent reagents were purchased
from Promega and the protocol was performed as previously described.60 Briefly, HeLa cells
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(30,000 cells/well) were cultured in an opaque 96-well plate with fresh EMEM containing 10%
FBS and 1% Anti-Anti and incubated overnight at 37 °C and 5% CO2. Cells were washed with
serum-free EMEM (SF-EMEM) before addition of fresh SF-EMEM and varying concentrations
of toxins to a total volume of 50 μL per well. Next, cells were incubated as above for 48 hours
before cooling to room temperature, washing as above, and replacing fresh SF-EMEM (50-100
μL) in wells. An equal volume of CellTiter-Glo® luminescent reagent was added, the plate was
agitated (2 min, ambient temp), and then luminescent data was acquired using a GENios Tecan
Microplate Reader.
In vitro inflammasome activation and cytokine expression level determination. Carrie
Cowardin, a collaborator in the Petri Lab at the University of Virginia, performed these
experiments with rTcdA toxin provided by the Feig Lab (data recently published).38 Briefly,
cultured mammalian cells (murine bone marrow derived dendritic cells, human THP-1
monocytes, murine raw macrophages) were incubated for 24 hours with various concentrations
of rTcdA-WT, rTcdA-NVN mutant, or neither (control), and in some cases lipopolysaccharide
(LPS) as a priming signal. Cells were lysed and subject to ELISA to establish protein
concentrations (CXCL1, IL-6, IL-1β, and Caspase 1). Quantitation of NF-κB upregulation i.e.,
inflammasome activation, was carried out with murine Raw-Blue™ macrophages, which are
modified to contain a secreted embryonic alkaline phosphatase (SEAP)-reporter construct that is
inducible by NF-κB. Culture media was surveyed by the QUANTI-Blue™ assay at A65061, 62 after
24 hours.
In vivo cytokine expression level determination. Carrie Cowardin from the University of
Virginia performed these experiments.38 In brief, mice underwent a cecal laparotomy;63 meaning
rTcdA-WT and rTcdA-NVN toxins were injected into the cecum (15 μg). After 8 hours, mice
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were sacrificed. Cecal tissues were obtained, lysed, and the supernatant was subject to ELISA in
order to quantitate cytokine production.
Immunohistochemistry staining and histological analysis. Carrie Cowardin (University
of Virginia) also performed these experiments. Again, toxin was injected to the cecum of mice
via laparotomy. Mice were then sacrificed after 8 hours as above. Cecal tissues were obtained,
fixed with Bouin’s solution (picric acid, acetic acid, formaldehyde) for 18 hours, embedded with
paraffin for rigidity, sectioned, and stained with hematoxylin and eosin to visualize nuclei and
the rest of the cell components, respectively.37, 38 Histology score was based on 5 parameters:
Submucosal edema, inflammatory infiltrate, epithelial disruption, luminal exudate, and mucosal
thickening.
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CHAPTER FOUR:
Cloning, Expression, and Purification of Clostridium difficile Recombinant Toxin B
The homologous C. diff enterotoxins A and B share 48% sequence identity,64 and as seen
in Figure 3, the main structural difference between the two resides within the length of the
CROP domain. Although TcdA/B exhibit similar mechanisms of infection and enzymatic
functions, TcdB is actually 100-fold more efficacious at initiating cytopathic cell rounding and
apoptotic cell death,41 most likely attributed to a shorter CROP domain that is less able to
occlude GTD and CPD activity.16, 48 Also in contrast to TcdA, high concentrations of TcdB have
been shown to cause necrotic cell death via an alternative NADPH oxidase-mediated pathway,
portraying the sudden depletion of cellular ATP, release of lactate dehydrogenase, and disruption
of the cell membrane.41, 65, 66 Interestingly, the necrosis phenotype has been revealed to persist in
cells treated with CPD/GTD-inactive TcdB mutants,65 indicating the sole necessity for
functioning TD39, 64 and CROP domains.41 To further advocate the potential importance of TcdBinduced necrosis regarding CDAD, studies show the elevated TcdB concentrations needed to
exhibit this phenotype not only correlate to pathological colonic epithelial damage, but also
compare to levels found in feces of clinical isolates with severe C. diff infection.65, 67 Lastly, there
are numerous hypervirulent and resistant C. diff strains emerging today, such as the early 2000s
epidemic strain NAPI/027/BI that is known for increased TcdA/B production (roughly 16-fold
and 23-fold, respectively) and ribotype 017, which is a sole producer of TcdB (A-B+).1, 68, 69
Because of the numerous aforementioned reasons, a more complete analysis of C. diff TcdB and
therapeutic methods that successfully target this toxin are clinically important, and as all
previous studies done in the Feig Lab have utilized C. diff TcdA, the cloning, expression, and
purification of toxin B was needed.
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Considering the great length of the TcdA/B genes, previous methods to clone rTcdA-WT
and rTcdA-NVN in the Feig Lab included splitting the gene into segments to avoid possible
errors in replication.53 Although this technique was successful, it is also strenuous and time
consuming. To sidestep previous methods, the DNA polymerase used to clone rTcdB was
upgraded to Q5® High-Fidelity polymerase, which has 3’ to 5’ exonuclease activity and an error
rate of roughly 100-fold lower than taq and
12-fold lower than pfu.70 Q5® polymerizes at
an extremely fast rate of 6 kb/min and has
shown to successfully replicate amplicons of
less than or equal to 20 kb,71 which is more
than 2.8 times the length of the targeted
7101 bp tcdb gene. Furthermore, Q5®
polymerase results in blunt ends, allowing
	
  
Figure 17: pHis1522 shuttle vector for B. meg
expression system. The pHis1522 plasmid allows for
ease of use between E. coli and B. meg, containing
specific replication origins (grey) and antibiotic
resistance genes (light blue) for each. Downstream of
the xylose isomerase promoter (PxylA’, dark red), the
multiple cloning site (magenta) is positioned in frame
with the xylose isomerase gene (xylA’, purple) with
specific BsrG1 and Kpn1 restriction cut sites shown in
pink. Finally, the transcriptional regulatory repressor of
xylose isomerase (xylR) is shown in cyan.
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uncomplicated

TOPO

cloning,

is

effective at manipulating DNA via sitedirected mutagenesis,71 and has proven here
to clone the entire tcdb gene without error.
Full length TcdA/B proteins are
rather large (308 kDa and 270 kDa,

respectively) and do not express well in E. coli, therefore the Bacillus megaterium (B. meg)
expression system (MoBiTec)72 known for oversized protein expression was used to provide a
route for holotoxin production. The pHis1522 plasmid utilized in this system (Figure 17),
possessing E. coli-specific ampicillin and B. meg-specific tetracycline resistance markers, is a
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shuttle vector with relieved codon bias that allows for DNA manipulation in E. coli before
transforming into B. meg for expression. Furthermore, the multiple cloning site within pHis1522
contains a built-in C-terminal 6X his tag and is positioned within xylA’ (xylose isomeraseencoding gene) to permit xylose induction of TcdA/B protein expression.72
A general overview of the C. diff tcdb cloning process, borrowed closely from Feng, et
al.,73 is illustrated in Figure 18. To begin, tcdb from C. diff genomic DNA (strain ATTC 9689D)
was isolated and amplified by PCR utilizing Q5® High-Fidelity polymerase and primers 1 and 2

	
  
Figure 18: Overview of rTcdB-WT cloning process. The 7121 bp tcdb gene was isolated from C. diff genomic
DNA (strain ATTC 9689D) and amplified via Q5® High-Fidelity DNA polymerase using primers 1 and 2, which
were designed to contain 5’ BsrG1 and 3’ Kpn1 restriction digest sites for convenient ligation into pHis1522
(7402 bp). Both tcdb and pHis1522 were purified, digested with BsrG1 and Kpn1 enzymes, and ligated together
using T4 DNA ligase to give the final expression plasmid pBMJ_130401 (14458 bp). TSS: transcriptional start
site for the xylA’ gene.
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Table 2: Primers for cloning rTcdB-WT and rTcdB-NVN.
Primer
Number

Name

Primer Sequences

1

TcdB_F

5' - GCGCTGTACAATGAGTTTAGTTAATAGAAAAC - 3'

2

TcdB_R

5' - ATATATGGTACCCTTCACTAATCACTAATTGAGC - 3'

3

B2R_2

5' - TTAATCTTAGGTCTATCAGAAATTATACTTG - 3'

4

rTcdB_NVN_F2

5' - GAAATTGGTGGTATGTATTTAaATGTTaATATGTTACCAGGAATACAACCAGAC - 3'

5

rTcdB_NVN_R2

5' - GTCTGGTTGTATTCCTGGTAACATATtAACATtTAAATACATACCACCAATTTC - 3'

NOTE: Bold: restriction enzyme site. Underlined: primer binding complementary site. Lower case: uncomplementary bases for SDM.

(Table 2), which were equipped with 5’ BsrG1 (primer 1; forward) and 3’ Kpn1 (primer 2;
reverse) restriction digest sites for convenient ligation into the multiple cloning site of the
pHis1522 shuttle vector. Following PCR, the expected amplicon size of 7121 bp (full tcdb gene
length plus primer overhang) was confirmed by
agarose gel electrophoresis and is shown in
Figure 19, where all attempted temperatures
within the gradient ranging from 49 °C to 61 °C
were effective for primer annealing and 53.4 °C
was

used

for

subsequent

scale-up

PCR

reactions.
Once clean and quantified by A260, the
C. diff tcdb amplicon and the shuttle vector

	
  
Figure 19: The tcdb gene was successfully
isolated from C. diff genomic DNA. Agarose gel
shows successful amplification of the 7121 bp tcdb
amplicon. All temperatures ranging from 49 °C-61
°C resulted in effective annealing and 53.4 °C was
used for following scale-up PCR reactions.

	
  
pHis1522 were digested with BsrG1 and Kpn1 restriction enzymes, ligated together using T4
DNA Ligase, and transformed into Top10 electrocompetent E. coli cells by electroporation. The
ampicillin resistance marker within pHis1522 was used to select for transformant colonies
containing viable plasmid, five of which were then isolated and purified. To confirm plasmid
length prior to sequencing, Xho1 and Spe1 restriction enzymes with plasmid-specific and toxinspecific cut sites, respectively, were used to confirm the correctly sized products of 8647 and
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Figure 20: Double digest verification for pBMJ_130401. A: Plasmid map of pBMJ_130401 depicts the tcdb
gene insert and Xho1/Spe1 digest sites used for determining correct plasmid size. B: DNA isolated from five
different colonies showed the expected products of 8647 and 5811 bp after Xho1/Spe1 digestion.

	
  
5811 bp (Figure 20). Primers shown in Table 3 subsequently verified the 7101 bp tcdb gene
sequence to contain no errors. Finally, the tcdb-pHis1522 plasmid, now renamed pBMJ_130401,
underwent transformation into B. meg for protein production. Figure 21 shows purified rTcdBWT at the correct size of 270 kDa, where a 16 hour expression period73 of 1 liter cells resulted in
roughly 1 mg of protein, which is roughly twice as much as toxin A per liter and most likely due
to protein length. Furthermore, incubation of HeLa cells with 0.2 nM rTcdB-WT caused
cytopathic rounding effects within a 2 hour period, proving the rTcdB-WT protein to be active
(Figure 21).
For negative control, just as was done for rTcdA-NVN,53 creation of the enzymatically
inactive mutant rTcdB-NVN is dependent upon the aspartate to asparagine mutation within the
active site of the GTD (D286N, D288N). To avoid producing error in the rest of the tcdb gene,
toxin B GTD was first isolated and PCR amplified from pBMJ_130401 (1946 bp, Figure 22A)
using primers 1 and 3 from Table 2, followed by direct ligation into TOPO vector
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Figure 21: SDS-PAGE gel of purified rTcdB-WT and cytopathic rounding effects of active protein. Left:
A clean band in the Ep (elutions pooled) lane shows the expected size of 270 kDa. M: marker. F: flowthrough.
B: binding buffer wash 1. W: wash buffer wash 2. E1: elution 1. Incubation of healthy HeLa cells (0 hours,
middle) with 0.2 nM rTcdB-WT for 2 hours resulted in characteristic cytopathic rounding effects (right).

	
  

Figure 22: Isolation and site-directed mutagenesis of
rTcdB-GTD. A: rTcdB-GTD was isolated and amplified
by PCR from pBMJ_130401 using primers 1 and 3 in
Table 1. All annealing temperatures between 55°C and
65°C resulted in the expected amplicon length of 1946 bp.
B: The GTD was then ligated into TOPO (pBMJ_70401;
5902 bp). Following transformation into E. coli cells and
kanamycin selection, the DNA from resultant colonies
underwent SDM using primers 4 and 5 to create D286N
and D288N mutations. Plasmid lengths were verified by
digestion with the BsrG1 and BsaB1 enzymes, to produce
digest products of 3690, 1641, and 571 bp. M: marker. P:
digestion reaction products.
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(pBMJ_70401; Figure 22B left), transformation into electrocompetent E. coli cells, and plating
on kanamycin antibiotic for selection. Again, select transformant colonies were grown overnight
to produce ample amounts of DNA that was then isolated and purified. Site-directed mutagenesis
via PCR with primers 4 and 5 (Table 2) was done to confer D286N and D288N mutations within
the GTD (pBMJ_70402), and digestion of the PCR product with BsrG1 and BsaB1 restriction
enzymes resulted in products of 3690, 1641, and 571 bp which confirmed correct plasmid length
as seen in Figure 22B. Although the smallest digest product of 571 bp ran below the indicated
500 bp marker, the first two bands and the overall digestion pattern within the gel seemed to be
correct, therefore the plasmid was sent forth for sequencing and verified via the primers in Table
4.

In order to create the final rTcdB-NVN B. meg expression plasmid, pBMJ_70402 and

pBMJ_130401 were digested with BsrG1 and BsaB1 to give the rTcdB-GTD-NVN (1641 bp)
and pHis1522-tcdb minus the GTD (12817 bp) products, which will need to undergo ligation and
transformation into B. meg.
For many reasons, comprehending toxin B functionality in comparison to toxin A, as well
as determining inhibitory treatment methods that are specified to each toxin is clinically
important for impeding CDAD as a whole. Not only do some hypervirulent strains express toxin
B as the sole virulence factor, but also TcdB is more potent in comparison to TcdA and it
contains a poorly understood pathogenic mechanism that results in necrotic epithelial cell death
in patients with CDAD. Experimentation pertaining to TcdA has been underway for quite some
time in the Feig Lab, but previous research utilizing TcdB has been very minimal since C. diff
toxins are rather costly and until now there wasn’t an obtainable TcdB expression plasmid.
Although the final ligation and transformation of the rTcdB-NVN plasmid have not been
completed at this point, the data presented here shows sequence verification for rTcdB-WT
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(pBMJ_130401; Appendix I) and the components of rTcdB-NVN (Appendix II), where
expression of rTcdB-WT resulted in ample amounts of active protein that will elicit further
mechanistic and inhibitory analysis of C. diff toxin B in the future.

Table 3: Sequencing primers for rTcdB-WT.

Table 4: Sequencing primers for rTcdB-NVN.
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CHAPTER FOUR METHODS
Clostridium difficile rTcdB-WT cloning. Procedure to isolate, clone, and express C. diff
toxin B was closely borrowed from Feng, et al.73 Here, C. diff genomic DNA (90556-M6S) was
purchased from ATTC™ (item number 9689D-5 DR), all primers were synthesized and
purchased from Sigma, and PCR reactions were done using a Bio-Rad MyCycler Thermo Cycler
(catalog #19209590). In short, rtcdb was isolated using primers 1 and 2 (Table 2) from C. diff
genomic DNA as follows:

tcdb Gene Isolation
Q5 RXN buffer
For Primer "TcdB_F"
Rev Primer "TcdB_R"
C. diff genomic DNA
dNTP's
Q5 High Fidelity DNA polymerase
Water
Total (µL)

[Stock]

[Final]

1X Vol
(µL)

5X
10 µM
10 µM

1X
0.5 µM
0.5 µM

4
1
1

20 ng/µL
10 mM
2 U/µL
-

20 ng
0.3 mM
0.004 U
-

1
0.6
0.2
12.2
20

98°C
2 min

98°C
30 s

72°C 72°C
14 min 20 min
49-61°C
30 s
30X

4°C
HOLD

Primers 1 and 2 were equipped with BsrG1 (forward) and Kpn1 (reverse) cut sites and an
annealing temperature of 53.4 °C was used to move forward. The tcdb amplicon was purified
using MicroElute Cycle Pure Kit Centrifugation Protocol (OMEGA), eluted in 10 mM Tris-HCl
pH 8.5, and quantified by A260. pHis1522 (MoBiTec) and the tcdb amplicon then underwent
double digestion with BsrG1 and Kpn1 restriction enzymes (3 μg DNA, 1X NEB 2.1 Reaction
Buffer, 30 U BsrG1, and 30 U Kpn1) at 37 °C for 4 hours (0.2 U of calf intestinal alkaline
phosphatase (CIP) was added to the pHis1522 plasmid digest reaction at the 3 hour mark). Next,
reactions were mixed with 1X crystal violet loading dye (5% glycerol, 3.3 mM EDTA, 16.6
μg/mL crystal violet), loaded onto a 0.8% agarose gel containing 1.6 mg/mL crystal violet,
separated by gel electrophoresis (80 V, 1 hr), and purified using the EZNA Gel Extraction Kit
(OMEGA). After quantitation at A260, pHis1522 and tcdb insert were ligated together (20 U T4
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DNA ligase, 1X T4 buffer, 50 ng pHis1522, 37.5 ng tcdb DNA) at RT for 15 min following a 10
min heat-inactivation period at 65 °C, transforming into top10 E. coli cells by electroporation
(1.5 μL ligation rxn, 75 μL competent cells), outgrowing in 200 μL standard LB broth (37 °C,
250 rpm, 30 min), plating on 100 μg/mL ampicillin plates, and incubating at 37 °C overnight.
Resulting colonies were miniprepped (OMEGA EZNA Plasmid DNA Mini Kit II) and
sequenced (Wayne State University School of Medicine Applied Genomics Technology Center)
with primers seen in Table 3. Successful sequencing of rtcdb is shown in Appendix I.
pHis1522-tcdb (pBMJ_130401) was transformed into B. meg, expressed, and purified as stated
previously (Chapter 2 Methods).
Clostridium difficile rTcdB-NVN cloning. Primers 1 and 3 from Table 2 were used to
isolate and amplify rtcdb-GTD as follows:
tcdb-GTD Isolation

[Stock]

taq RXN buffer

[Final]

1X Vol
(µL)

10X

1X

2

For Primer "TcdB_F"

10 µM

0.5 µM

1

95°C

Rev Primer "B2R_2"

10 µM

0.5 µM

1

30 s

DNA (pBMJ_130401)

2.86 ng/µL

0.5 ng

0.175

MgCl 2
dNTP's

15 mM
10 mM

1.5 mM
0.5 mM

2
1

taq polymerase

5 U/µL

0.625 U

0.125

-

-

12.7

-

-

20

Water
Total (µL)

95°C
30 s

68°C 68°C
2 min 5 min
55-65°C
45 s
25X

4°C
HOLD

The PCR reaction with annealing temperature of 61.1 °C was used to move forward. Ligation of
tcdb-GTD into pCR-XL-TOPO vector was performed at a 3:1 insert to vector ratio (RT, 30 min)
before transforming into top 10 E. coli cells and plating on amp LB-agar plates as above.
Selected colonies were then miniprepped (OMEGA EZNA Plasmid DNA Mini Kit II) and
resulting DNA (pBMJ_70401) was used with primers 4 and 5 (Table 2) to create D286N/D288N
mutations as follows:
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tcdb-NVN SDM PCR
pfu RXN buffer
For Primer "rTcdB_NVN_F2"
Rev Primer "rTcdB_NVN_R2"

[Stock]

[Final]

1X Vol
(µL)

10X

1X

2.5

10 µM

0.25 µM

0.625

10 µM

0.25 µM

0.625

10 ng/µL

10 ng

1

dNTP's

10 mM

0.2 mM

0.5

pfu DNA polymerase
Water

5 U/µL
-

1.25 U
-

0.25
19.5

-

-

25

DNA (pBMJ_70401)

Total (µL)

95°C 95°C
2.5 min 1 min

72°C 72°C
12 min 1 min
55°C
1 min

4°C
12X

HOLD

Sequencing of pBMJ_70402 was done using primers in Table 4 and verification can be seen in
Appendix II.
HeLa cell cultures. HeLa cell cultures were obtained from the Pflum Lab (Wayne State
University) and contained to BL2 standard protocols. See Chapter 3 Methods for further
maintenance procedures and protocols utilizing HeLa cells. Visual cell killing assays were done
as described in Chapter 2 Methods with the exception of adding HQS-Epoxy inhibitor peptide.
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FINAL_pHIS1522_TcdB_BMJ.ape (pBMJ_130401; colony 1). Any errors/mismatches were confirmed manually by chromatogram.
From 16 to 7126 alignment to
3591_B01_TcdB1__B1R_007.seq-- Matches:225; Mismatches:0; Gaps:6906; Unattempted:0
3591_C01_TcdB1__B2F_006.seq-- Matches:882; Mismatches:0; Gaps:6229; Unattempted:0
3591_D01_TcdB1__B2R_005.seq-- Matches:709; Mismatches:0; Gaps:6402; Unattempted:0
3591_F01_TcdB1__B3R_003.seq-- Matches:849; Mismatches:1; Gaps:6261; Unattempted:0
3591_H01_TcdB1__B4R_001.seq-- Matches:766; Mismatches:0; Gaps:6345; Unattempted:0
3591_A02_TcdB1__B5F_008.seq-- Matches:816; Mismatches:0; Gaps:6295; Unattempted:0
3591_B02_TcdB1__B5R_007.seq-- Matches:197; Mismatches:2; Gaps:6912; Unattempted:0
3591_C02_TcdB1__B6F_006.seq-- Matches:444; Mismatches:0; Gaps:6667; Unattempted:0
3591_D02_TcdB1__B6R_005.seq-- Matches:752; Mismatches:0; Gaps:6359; Unattempted:0
3591_E02_TcdB1__B7F_004.seq-- Matches:995; Mismatches:0; Gaps:6116; Unattempted:0
3591_G02_TcdB1__B8F_002.seq-- Matches:579; Mismatches:0; Gaps:6543; Unattempted:0
*
*
*
*
*
*
*
*
*
*
16>~~~~~~~~~~~~~~~~~~~~tgtacaATGAGTTTAGTTAATAGAAAACAGTTAGAAAAAATGGCAAATGTAAGATTTCGTACTCAAGAAGATGAATATGT>95
348<ACTTAAATCAAAGGGGGAAATGTACAATGAGTTTAGTTAATAGAAAACAGTTAGAAAAAATGGCAAATGTAAGATTTCGTACTCAAGAAGATGAATATGT<249
67>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>67
813<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<813
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
96>TGCAATATTGGATGCTTTAGAAGAATATCATAATATGTCAGAGAATACTGTAGTCGAAAAATATTTAAAATTAAAAGATATAAATAGTTTAACAGATATT>195
248<TGCAATATTGGATGCTTTAGAAGAATATCATAATATGTCAGAGAATACTGTAGTCGAAAAATATTTAAAATTAAAAGATATAAATAGTTTAACAGATATT<149
67>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>67
813<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<813
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
196>TATATAGATACATATAAAAAATCTGGTAGAAATAAAGCCTTAAAAAAATTTAAGGAATATCTAGTTACAGAAGTATTAGAGCTAAAGAATAATAATTTAA>295
148<TATATAGATACATATAAAAAATCTGGTAGAAATAAAGCCTTAAAA~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~CTTAAAAAAATTTAAGGAATATCTAGTTACAGAAGTATTAGAGCTAAAGAATAATAATTTAA>129
813<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<813
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
296>CTCCAGTTGAGAAAAATTTACATTTTGTTTGGATTGGAGGTCAAATAAATGACACTGCTATTAATTATATAAATCAATGGAAAGATGTAAATAGTGATTA>395
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
130>CTCCAGTTGAGAAAAATTTACATTTTGTTTGGATTGGAGGTCAAATAAATGACACTGCTATTAATTATATAAATCAATGGAAAGATGTAAATAGTGATTA>229
813<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<813
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
396>TAATGTTAATGTTTTTTATGATAGTAATGCATTTTTGATAAACACATTGAAAAAAACTGTAGTAGAATCAGCAATAAATGATACACTTGAATCATTTAGA>495
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
230>TAATGTTAATGTTTTTTATGATAGTAATGCATTTTTGATAAACACATTGAAAAAAACTGTAGTAGAATCAGCAATAAATGATACACTTGAATCATTTAGA>329
813<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<813
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341

45
*
*
*
*
*
*
*
*
*
*
496>GAAAACTTAAATGACCCTAGATTTGACTATAATAAATTCTTCAGAAAACGTATGGAAATAATTTATGATAAACAGAAAAATTTCATAAACTACTATAAAG>595
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
330>GAAAACTTAAATGACCCTAGATTTGACTATAATAAATTCTTCAGAAAACGTATGGAAATAATTTATGATAAACAGAAAAATTTCATAAACTACTATAAAG>429
813<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<813
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
596>CTCAAAGAGAAGAAAATCCTGAACTTATAATTGATGATATTGTAAAGACATATCTTTCAAATGAGTATTCAAAGGAGATAGATGAACTTAATACCTATAT>695
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
430>CTCAAAGAGAAGAAAATCCTGAACTTATAATTGATGATATTGTAAAGACATATCTTTCAAATGAGTATTCAAAGGAGATAGATGAACTTAATACCTATAT>529
813<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<813
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
696>TGAAGAATCCTTAAATAAAATTACACAGAATAGTGGAAATGATGTTAGAAACTTTGAAGAATTTAAAAATGGAGAGTCATTCAACTTATATGAACAAGAG>795
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
530>TGAAGAATCCTTAAATAAAATTACACAGAATAGTGGAAATGATGTTAGAAACTTTGAAGAATTTAAAAATGGAGAGTCATTCAACTTATATGAACAAGAG>629
813<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<813
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
796>TTGGTAGAAAGGTGGAATTTAGCTGCTGCTTCTGACATATTAAGAATATCTGCATTAAAAGAAATTGGTGGTATGTATTTAGATGTTGATATGTTACCAG>895
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
630>TTGGTAGAAAGGTGGAATTTAGCTGCTGCTTCTGACATATTAAGAATATCTGCATTAAAAGAAATTGGTGGTATGTATTTAGATGTTGATATGTTACCAG>729
813<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<813
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
896>GAATACAACCAGACTTATTTGAGTCTATAGAGAAACCTAGTTCAGTAACAGTGGATTTTTGGGAAATGACAAAGTTAGAAGCTATAATGAAATACAAAGA>995
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
730>GAATACAACCAGACTTATTTGAGTCTATAGAGAAACCTAGTTCAGTAACAGTGGATTTTTGGGAAATGACAAAGTTAGAAGCTATAATGAAATACAAAGA>829
813<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<813
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
996>ATATATACCAGAATATACCTCAGAACATTTTGACATGTTAGACGAAGAAGTTCAAAGTAGTTTTGAATCTGTTCTAGCTTCTAAGTCAGATAAATCAGAA>1095
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
830>ATATATACCAGAATATACCTCAGAACATTTTGACATGTTAGACGAAGAAGTTCAAAGTAGTTTTGAATCTGTTCTAGCTTCTAAGTCAGATAAATCAGAA>929
813<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<813
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
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*
*
*
*
*
*
*
*
*
*
1096>ATATTCTCATCACTTGGTGATATGGAGGCATCACCACTAGAAGTTAAAATTGCATTTAATAGTAAGGGTATTATAAATCAAGGGCTAATTTCTGTGAAAG>1195
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
930>ATATTCTCATCACTTGGTGA~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
812<~~~~~~~~~~~~CTTGGTGATATGGAGGCATCACCACTAGAAGTTAAAATTGCATTTAATAGTAAGGGTATTATAAATCAAGGGCTAATTTCTGTGAAAG<725
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
1196>ACTCATATTGTAGCAATTTAATAGTAAAACAAATCGAGAATAGATATAAAATATTGAATAATAGTTTAAATCCAGCTATTAGCGAGGATAATGATTTTAA>1295
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
724<ACTCATATTGTAGCAATTTAATAGTAAAACAAATCGAGAATAGATATAAAATATTGAATAATAGTTTAAATCCAGCTATTAGCGAGGATAATGATTTTAA<625
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
1296>TACTACAACGAATACCTTTATTGATAGTATAATGGCTGAAGCTAATGCAGATAATGGTAGATTTATGATGGAACTAGGAAAGTATTTAAGAGTTGGTTTC>1395
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
624<TACTACAACGAATACCTTTATTGATAGTATAATGGCTGAAGCTAATGCAGATAATGGTAGATTTATGATGGAACTAGGAAAGTATTTAAGAGTTGGTTTC<525
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
1396>TTCCCAGATGTTAAAACTACTATTAACTTAAGTGGCCCTGAAGCATATGCGGCAGCTTATCAAGATTTATTAATGTTTAAAGAAGGCAGTATGAATATCC>1495
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
524<TTCCCAGATGTTAAAACTACTATTAACTTAAGTGGCCCTGAAGCATATGCGGCAGCTTATCAAGATTTATTAATGTTTAAAGAAGGCAGTATGAATATCC<425
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
1496>ATTTGATAGAAGCTGATTTAAGAAACTTTGAAATCTCTAAAACTAATATTTCTCAATCAACTGAACAAGAAATGGCTAGCTTATGGTCATTTGACGATGC>1595
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
424<ATTTGATAGAAGCTGATTTAAGAAACTTTGAAATCTCTAAAACTAATATTTCTCAATCAACTGAACAAGAAATGGCTAGCTTATGGTCATTTGACGATGC<325
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
1596>AAGAGCTAAAGCTCAATTTGAAGAATATAAAAGGAATTATTTTGAAGGTTCTCTTGGTGAAGATGATAATCTTGATTTTTCTCAAAATATAGTAGTTGAC>1695
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
324<AAGAGCTAAAGCTCAATTTGAAGAATATAAAAGGAATTATTTTGAAGGTTCTCTTGGTGAAGATGATAATCTTGATTTTTCTCAAAATATAGTAGTTGAC<225
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
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*
*
*
*
*
*
*
*
*
*
1696>AAGGAGTATCTTTTAGAAAAAATATCTTCATTAGCAAGAAGTTCAGAGAGAGGATATATACACTATATTGTTCAGTTACAAGGAGATAAAATTAGTTATG>1795
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
224<AAGGAGTATCTTTTAGAAAAAATATCTTCATTAGCAAGAAGTTCAGAGAGAGGATATATACACTATATTGTTCAGTTACAAGGAGATAAAATTAGTTATG<125
997<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<997
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
1796>AAGCAGCATGTAACTTATTTGCAAAGACTCCTTATGaTAGTGTACTATTTCAGAAAAATATAGAAGATTCAGAAATTGCATATTATTATAATCCTGGAGA>1895
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
124<AAGCAGCATGTAACTTATTTG~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
996<~~~~~~~~~~~~~CTTATTTGCAAAGACTCCTTATGATAGTGTACTATTTCAGAAAAATATAGAAGATTCAGAAATTGCATATTATTATAATCCTGGAGA<910
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
1896>TGGTGAAATACAAGAAATAGACAAGTATAAAATTCCAAGTATAATTTCTGATAGACCTAAGATTAAATTAACATTTATTGGTCATGGTAAAGATGAATTT>1995
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
909<TGGTGAAATACAAGAAATAGACAAGTATAAAATTCCAAGTATAATTTCTGATAGACNTAAGATTAAATTAACATTTATTGGTCATGGTAAAGATGAATTT<810
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
1996>AATACTGATATATTTGCAGGTTTTGATGTAGATTCATTATCCACAGAAATAGAAGCAGCAATAGATTTAGCTAAAGAGGATATTTCTCCTAAGTCAATAG>2095
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
809<AATACTGATATATTTGCAGGTTTTGATGTAGATTCATTATCCACAGAAATAGAAGCAGCAATAGATTTAGCTAAAGAGGATATTTCTCCTAAGTCAATAG<710
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
2096>AAATAAATTTATTAGGATGTAATATGTTTAGCTACTCTATCAACGTAGAGGAGACTTATCCTGGAAAATTATTACTTAAAGTTAAAGATAAAATATCAGA>2195
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
709<AAATAAATTTATTAGGATGTAATATGTTTAGCTACTCTATCAACGTAGAGGAGACTTATCCTGGAAAATTATTACTTAAAGTTAAAGATAAAATATCAGA<610
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
2196>ATTAATGCCATCTATAAGTCAAGACTCTATTATAGTAAGTGCAAATCAATATGAAGTTAGAATAAATAGTGAAGGAAGAAGAGAATTATTGGATCATTCT>2295
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
609<ATTAATGCCATCTATAAGTCAAGACTCTATTATAGTAAGTGCAAATCAATATGAAGTTAGAATAAATAGTGAAGGAAGAAGAGAATTATTGGATCATTCT<510
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848

48
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
2296>GGTGAATGGATAAATAAAGAAGAAAGTATTATAAAGGATATTTCATCAAAAGAATATATATCATTTAATCCTAAAGAAAATAAAATTACAGTAAAATCTA>2395
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
509<GGTGAATGGATAAATAAAGAAGAAAGTATTATAAAGGATATTTCATCAAAAGAATATATATCATTTAATCCTAAAGAAAATAAAATTACAGTAAAATCTA<410
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
2396>AAAATTTACCTGAGCTATCTACATTATTACAAGAAATTAGAAATAATTCTAATTCAAGTGATATTGAACTAGAAGAAAAAGTAATGTTAACAGAATGTGA>2495
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
409<AAAATTTACCTGAGCTATCTACATTATTACAAGAAATTAGAAATAATTCTAATTCAAGTGATATTGAACTAGAAGAAAAAGTAATGTTAACAGAATGTGA<310
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
2496>GATAAATGTTATTTCAAATATAGATACGCAAATTGTTGAGGAAAGGATTGAAGAAGCTAAGAATTTAACTTCTGACTCTATTAATTATATAAAAGATGAA>2595
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
309<GATAAATGTTATTTCAAATATAGATACGCAAATTGTTGAGGAAAGGATTGAAGAAGCTAAGAATTTAACTTCTGACTCTATTAATTATATAAAAGATGAA<210
972<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<972
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
2596>TTTAAACTAATAGAATCTATTTCTGATGCACTATGTGACTTAAAACAACAGAATGAATTAGAAGATTCTCATTTTATATCTTTTGAGGACATATCAGAGA>2695
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
209<TTTAAACTAATAGAATCTATTTCTGATGCACTATGTGACTTAAAACAACAGAATGAATTAGAA~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
971<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~GAATGAATTAGAAGATTCTCATTTTATATCTTTTGAGGACATATCAGAGA<922
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
2696>CTGATGAGGGATTTAGTATAAGATTTATTAATAAAGAAACTGGAGAATCTATATTTGTAGAAACTGAAAAAACAATATTCTCTGAATATGCTAATCATAT>2795
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
921<CTGATGAGGGATTTAGTATAAGATTTATTAATAAAGAAACTGGAGAATCTATATTTGTAGAAACTGAAAAAACAATATTCTCTGAATATGCTAATCATAT<822
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
2796>AACTGAAGAGATTTCTAAGATAAAAGGTACTATATTTGATACTGTAAATGGTAAGTTAGTAAAAAAAGTAAATTTAGATACTACACACGAAGTAAATACT>2895
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
821<AACTGAAGAGATTTCTAAGATAAAAGGTACTATATTTGATACTGTAAATGGTAAGTTAGTAAAAAAAGTAAATTTAGATACTACACACGAAGTAAATACT<722
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68

49
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
2896>TTAAATGCTGCATTTTTTATACAATCATTAATAGAATATAATAGTTCTAAAGAATCTCTTAGTAATTTAAGTGTAGCAATGAAAGTCCAAGTTTACGCTC>2995
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
721<TTAAATGCTGCATTTTTTATACAATCATTAATAGAATATAATAGTTCTAAAGAATCTCTTAGTAATTTAAGTGTAGCAATGAAAGTCCAAGTTTACGCTC<622
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
2996>AATTATTTAGTACTGGTTTAAATACTATTACAGATGCAGCCAAAGTTGTTGAATTAGTATCAACTGCATTAGATGAAACTATAGACTTACTTCCTACATT>3095
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
621<AATTATTTAGTACTGGTTTAAATACTATTACAGATGCAGCCAAAGTTGTTGAATTAGTATCAACTGCATTAGATGAAACTATAGACTTACTTCCTACATT<522
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
3096>ATCTGAAGGATTACCTATAATTGCAACTATTATAGATGGTGTAAGTTTAGGTGCAGCAATCAAAGAGCTAAGTGAAACGAGTGACCCATTATTAAGACAA>3195
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
521<ATCTGAAGGATTACCTATAATTGCAACTATTATAGATGGTGTAAGTTTAGGTGCAGCAATCAAAGAGCTAAGTGAAACGAGTGACCCATTATTAAGACAA<422
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
3196>GAAATAGAAGCTAAGATAGGTATAATGGCAGTAAATTTAACAACAGCTACAACTGCAATCATTACTTCATCTTTGGGGgTAGCTAGTGGATTTAGTATAC>3295
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
421<GAAATAGAAGCTAAGATAGGTATAATGGCAGTAAATTTAACAACAGCTACAACTGCAATCATTACTTCATCTTTGGGGGTAGCTAGTGGATTTAGTATAC<322
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
3296>TTTTAGTTCCTTTAGCAGGAATTTCAGCAGGTATACCAAGCTTAGTAAACAATGAACTTGTACTTCGAGATAAGGCAACAAAGGTTGTAGATTATTTTAA>3395
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
321<TTTTAGTTCCTTTAGCAGGAATTTCAGCAGGTATACCAAGCTTAGTAAACAATGAACTTGTACTTCGAGATAAGGCAACAAAGGTTGTAGATTATTTTAA<222
63>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>63
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
3396>ACATGTTTCATTAGTTGAAACTGAAGGAGTATTTACTTTATTAGATGATAAAATAATGATGCCACAAGATGATTTAGTGATATCAGAAATAGATTTTAAT>3495
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
221<ACATGTTTCATTAGTT~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
64>~~~~GTTTCATTAGTTGAAACTGAAGGAGTATTTACTTTATTAGATGATAAAATAATGATGCCACAAGATGATTTAGTGATATCAGAAATAGATTTTAAT>159
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232

50
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
3496>AATAATTCAATAGTTTTAGGTAAATGTGAAATCTGGAGAATGGAAGGTGGTTCAGGTCATACTGTAACTGATGATATAGATCACTTCTTTTCAGCACCAT>3595
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
160>AATAATTCAATAGTTTTAGGTAAATGTGAAATCTGGAGAATGGAAGGTGGTTCAGGTCATACTGTAACTGATGATATAGATCACTTCTTTTCAGCACCAT>259
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
3596>CAATAACATATAGAGAGCCACACTTATCTATATATGACGTATTGGAAGTACAAAAAGAAGAACTTGATTTGTCAAAAGATTTAATGGTATTACCTAATGC>3695
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
260>CAATAACATATAGAGAGCCACACTTATCTATATATGACGTATTGGAAGTACAAAAAGAAGAACTTGATTTGTCAAAAGATTTAATGGTATTACCTAATGC>359
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
3696>TCCAAATAGAGTATTTGCTTGGGAAACAGGATGGACACCAGGTTTAAGAAGCTTAGAAAATGATGGCACAAAACTGTTAGACCGTATAAGAGATAACTAT>3795
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
360>TCCAAATAGAGTATTTGCTTGGGAAACAGGATGGACACCAGGTTTAAGAAGCTTAGAAAATGATGGCACAAAACTGTTAGACCGTATAAGAGATAACTAT>459
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
3796>GAAGGTGAGTTTTATTGGAGATATTTTGCTTTTATAGCTGATGCTTTAATAACAACATTAAAACCAAGATATGAAGATACTAATATAAGAATAAATTTAG>3895
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
460>GAAGGTGAGTTTTATTGGAGATATTTTGCTTTTATAGCTGATGCTTTAATAACAACATTAAAACCAAGATATGAAGATACTAATATAAGAATAAATTTAG>559
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
3896>ATAGTAATACTAGAAGTTTTATAGTTCCAATAATAACTACAGAATATATAAGAGAAAAATTATCATATTCTTTCTATGGTTCAGGAGGAACTTATGCATT>3995
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
560>ATAGTAATACTAGAAGTTTTATAGTTCCAATAATAACTACAGAATATATAAGAGAAAAATTATCATATTCTTTCTATGGTTCAGGAGGAACTTATGCATT>659
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
3996>GTCTCTTTCTCAATATAATATGGGTATAAATATAGAATTAAGTGAAAGTGATGTTTGGATTATAGATGTTGATAATGTTGTGAGAGATGTAACTATAGAA>4095
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
660>GTCTCTTTCTCAATATAATATGGGTATAAATATAGAATTAAGTGAAAGTGATGTTTGGATTATAGATGTTGATAATGTTGTGAGAGATGTAACTATAGAA>759

51

*
*
*
*
*
*
*
*
*
*
4096>TCTGATAAAATTAAAAAAGGTGATTTAATAGAAGGTATTTTATCTACACTAAGTATTGAAGAGAATAAAATTATCTTAAATAGCCATGAGATTAATTTTT>4195
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
760>TCTGATAAAATTAAAAAAGGTGATTTAATAGAAGGTATTTTATCTACACTAAGTATTGAAGAGAATAAAATTATCTTAAATAGCCATGAGATTAATTTTT>859
232<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<232
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
4196>CTGGTGAGGTAAATGGAAGTAATGGATTTGTTTCTTTAACATTTTCAATTTTAGAAGGAATAAATGCAATTATAGAAGTTGATTTATTATCTAAATCATA>4295
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
860>CTGGTGAGGTAAATGGAAGT~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
231<~~~~~~~~~~AAATGGAAGTAATGGATTTGTTTCTTTAACATTTTCAATTTTAGAAGGAATAAATGCAATTATAGAAGTTGATTTATTATCTAAATCATA<142
68>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>68
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
4296>TAAATTACTTATTTCTGGCGAATTAAAAATATTGATGTTAAATTCAAATCATATTCAACAGAAAATAGATTATATAGGATTCAATAGCGAATTACAGAAA>4395
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
141<TAAATTACTTATTTCTGGCGAATTAAAAATATTGATGTTAAATTCAAATCATATTCAACAGAAAATAGATTATATAGGANNCAATAGCGAATTACAGAAA<42
69>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~GAAA>72
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
4396>AATATACCATATAGCTTTGTAGATAGTGAAGGAAAAGAGAATGGTTTTATTAATGGTTCAACAAAAGAAGGTTTATTTGTATCTGAATTACCTGATGTAG>4495
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
41<AATATACCA~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
73>AATATACCATATAGCTTTGTAGATAGTGAAGGAAAAGAGAATGGTTTTATTAATGGTTCAACAAAAGAAGGTTTATTTGTATCTGAATTACCTGATGTAG>172
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
4496>TTCTTATAAGTAAGGTTTATATGGATGATAGTAAGCCTTCATTTGGATATTATAGTAATAATTTGAAAGATGTCAAAGTTATAACTAAAGATAATGTTAA>4595
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
173>TTCTTATAAGTAAGGTTTATATGGATGATAGTAAGCCTTCATTTGGATATTATAGTAATAATTTGAAAGATGTCAAAGTTATAACTAAAGATAATGTTAA>272
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
4596>TATATTAACAGGTTATTATCTTAAGGATGATATAAAAATCTCTCTTTCTTTGACTCTACAAGATGAAAAAACTATAAAGTTAAATAGTGTGCATTTAGAT>4695
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206

52
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
273>TATATTAACAGGTTATTATCTTAAGGATGATATAAAAATCTCTCTTTCTTTGACTCTACAAGATGAAAAAACTATAAAGTTAAATAGTGTGCATTTAGAT>372
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
4696>GAAAGTGGAGTAGCTGAGATTTTGAAGTTCATGAATAGAAAAGGTAATACAAATACTTCAGATTCTTTAATGAGCTTTTTAGAAAGTATGAATATAAAAA>4795
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
373>GAAAGTGGAGTAGCTGAGATTTTGAAGTTCATGAATAGAAAAGGTAATACAAATACTTCAGATTCTTTAATGAGCTTTTTAGAAAGTATGAATATAAAAA>472
848<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<848
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
4796>GTATTTTCGTTAATTTCTTACAATCTAATATTAAGTTTATATTAGATGCTAATTTTATAATAAGTGGTACTACTTCTATTGGCCAATTTGAGTTTATTTG>4895
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
473>GTATTTTCGTTAATTTCTTACAATCTAATATTAAGTTTAT~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
847<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~AAGTTTATATTAGATGCTAATTTTATAATAAGTGGTACTACTTCTATTGGCCAATTTGAGTTTATTTG<780
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
4896>TGATGAAAATGATAATATACAACCATATTTCATTAAGTTTAATACACTAGAAACTAATTATACTTTATATGTAGGAAATAGACAAAATATGATAGTGGAA>4995
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
779<TGATGAAAATGATAATATACAACCATATTTCATTAAGTTTAATACACTAGAAACTAATTATACTTTATATGTAGGAAATAGACAAAATATGATAGTGGAA<680
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
4996>CCAAATTATGATTTAGATGATTCTGGAGATATATCTTCAACTGTTATCAATTTCTCTCAAAAGTATCTTTATGGAATAGACAGTTGTGTTAATAAAGTTG>5095
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
679<CCAAATTATGATTTAGATGATTCTGGAGATATATCTTCAACTGTTATCAATTTCTCTCAAAAGTATCTTTATGGAATAGACAGTTGTGTTAATAAAGTTG<580
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
5096>TAATTTCACCAAATATTTATACAGATGAAATAAATATAACGCCTGTATATGAAACAAATAATACTTATCCAGAAGTTATTGTATTAGATGCAAATTATAT>5195
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
579<TAATTTCACCAAATATTTATACAGATGAAATAAATATAACGCCTGTATATGAAACAAATAATACTTATCCAGAAGTTATTGTATTAGATGCAAATTATAT<480
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
5196>AAATGAAAAAATAAATGTTAATATCAATGATCTATCTATACGATATGTATGGAGTAATGATGGTAATGATTTTATTCTTATGTCAACTAGTGAAGAAAAT>5295
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147

53
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
479<AAATGAAAAAATAAATGTTAATATCAATGATCTATCTATACGATATGTATGGAGTAATGATGGTAATGATTTTATTCTTATGTCAACTAGTGAAGAAAAT<380
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
5296>AAGGTGTCACAAGTTAAAATAAGATTCGTTAATGTTTTTAAAGATAAGACTTTGGCAAATAAGCTATCTTTTAACTTTAGTGATAAACAAGATGTACCTG>5395
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
379<AAGGTGTCACAAGTTAAAATAAGATTCGTTAATGTTTTTAAAGATAAGACTTTGGCAAATAAGCTATCTTTTAACTTTAGTGATAAACAAGATGTACCTG<280
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
5396>TAAGTGAAATAATCTTATCATTTACACCTTCATATTATGAGGATGGATTGATTGGCTATGATTTGGGTCTAGTTTCTTTATATAATGAGAAATTTTATAT>5495
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
279<TAAGTGAAATAATCTTATCATTTACACCTTCATATTATGAGGATGGATTGATTGGCTATGATTTGGGTCTAGTTTCTTTATATAATGAGAAATTTTATAT<180
24>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>24
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
5496>TAATAACTTTGGAATGATGGTATCTGGATTAATATATATTAATGATTCATTATATTATTTTAAACCACCAGTAAATAATTTGATAACTGGATTTGTGACT>5595
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
179<TAATAACTTTGGAATGATGGTATCTGGATTAATATATATTAATGATTCATTATATTATTTTAAACCACCAGTAAATAATTTGAT~~~~~~~~~~~~~~~~<96
25>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~CCAGTAAATAATTTGATAACTGGATTTGTGACT>57
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
5596>GTAGGCGATGATAAATACTACTTTAATCCAATTAATGGTGGAGCTGCTTCAATTGGAGAGACAATAATTGATGACAAAAATTATTATTTCAACCAAAGTG>5695
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
58>GTAGGCGATGATAAATACTACTTTAATCCAATTAATGGTGGAGCTGCTTCAATTGGAGAGACAATAATTGATGACAAAAATTATTATTTCAACCAAAGTG>157
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
5696>GAGTGTTACAAACAGGTGTATTTAGTACAGAAGATGGATTTAAATATTTTGCCCCAGCTAATACACTTGATGAAAACCTAGAAGGAGAAGCAATTGATTT>5795
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
158>GAGTGTTACAAACAGGTGTATTTAGTACAGAAGATGGATTTAAATATTTTGCCCCAGCTAATACACTTGATGAAAACCTAGAAGGAGAAGCAATTGATTT>257
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
5796>TACTGGAAAATTAATTATTGACGAAAATATTTATTATTTTGATGATAATTATAGAGGAGCTGTAGAATGGAAAGAATTAGATGGTGAAATGCACTATTTT>5895
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104

54
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
258>TACTGGAAAATTAATTATTGACGAAAATATTTATTATTTTGATGATAATTATAGAGGAGCTGTAGAATGGAAAGAATTAGATGGTGAAATGCACTATTTT>357
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
5896>AGCCCAGAAACAGGTAAAGCTTTTAAAGGTCTAAATCAAATAGGTGATTATAAATACTATTTCAATTCTGATGGAGTTATGCAAAAAGGATTTGTTAGTA>5995
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
358>AGCCCAGAAACAGGTAAAGCTTTTAAAGGTCTAAATCAAATAGGTGATTATAAATACTATTTCAATTCTGATGGAGTTATGCAAAAAGGATTTGTTAGTA>457
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
5996>TAAATGATAATAAACACTATTTTGATGATTCTGGTGTTATGAAAGTAGGTTACACTGAAATAGATGGCAAGCATTTCTACTTTGCTGAAAACGGAGAAAT>6095
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
458>TAAATGATAATAAACACTATTTTGATGATTCTGGTGTTATGAAAGTAGGTTACACTGAAATAGATGGCAAGCATTTCTACTTTGCTGAAAACGGAGAAAT>557
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
6096>GCAAATAGGAGTATTTAATACAGAAGATGGATTTAAATATTTTGCTCATCATAATGAAGATTTAGGAAATGAAGAAGGTGAAGAAATCTCATATTCTGGT>6195
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
558>GCAAATAGGAGTATTTAATACAGAAGATGGATTTAAATATTTTGCTCATCATAATGAAGATTTAGGAAATGAAGAAGGTGAAGAAATCTCATATTCTGGT>657
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
6196>ATATTAAATTTCAATAATAAAATTTACTATTTTGATGATTCATTTACAGCTGTAGTTGGATGGAAAGATTTAGAGGATGGTTCAAAGTATTATTTTGATG>6295
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
658>ATATTAAATTTCAATAATAAAATTTACTATTTTGATGATTCATTTACAGCTGTAGTTGGATGGAAAGATTTAGAGGATGGTTCAAAGTATTATTTTGATG>757
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
6296>AAGATACAGCAGAAGCATATATAGGTTTGTCATTAATAAATGATGGTCAATATTATTTTAATGATGATGGAATTATGCAAGTTGGATTTGTCACTATAAA>6395
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
758>AAGATACAGCAGAAGCATATATAGGTTTGTCATTAATAAATGATGGTCAATATTATTTTAATGATGATGGAATTATGCAAGTTGGATTTGTCACTATAAA>857
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
6396>TGATAAAGTCTTCTACTTCTCTGACTCTGGAATTATAGAATCTGGAGTACAAAACATAGATGACAATTATTTCTATATAGATGATAATGGTATAGTTCAA>6495
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949

55
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
858>TGATAAAGTCTTCTACTTCTCTGACTCTGGAATTATAGAATCTGGAGTACAAAACATAGATGACAATTATTTCTATATAGATGATAATGGTATAGTTCAA>957
341>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>341
*
*
*
*
*
*
*
*
*
*
6496>ATTGGTGTATTTGATACTTCAGATGGATATAAATATTTTGCACCTGCTAATACTGTAAATGATAATATTTACGGACAAGCAGTTGAATATAGTGGTTTAG>6595
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
958>ATTGGTGTATTTGATACTTCAGATGGATATAAATATTTTGCACCTGCTAATACTGTAAATGA~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>1019
342>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~CTGTAAATGATAATATTTACGGACAAGCAGTTGAATATAGTGGTTTAG>389
*
*
*
*
*
*
*
*
*
*
6596>TTAGAGTTGGGGAAGATGTATATTATTTTGGAGAAACATATACAATTGAGACTGGATGGATATATGATATGGAAAATGAAAGTGATAAATATTATTTCAA>6695
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
1019>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>1019
390>TTAGAGTTGGGGAAGATGTATATTATTTTGGAGAAACATATACAATTGAGACTGGATGGATATATGATATGGAAAATGAAAGTGATAAATATTATTTCAA>489
*
*
*
*
*
*
*
*
*
*
6696>TCCAGAAACTAAAAAAGCATGCAAAGGTATTAATTTAATTGATGATATAAAATATTATTTTGATGAGAAGGGCATAATGAGAACGGGTCTTATATCATTT>6795
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
1019>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>1019
490>TCCAGAAACTAAAAAAGCATGCAAAGGTATTAATTTAATTGATGATATAAAATATTATTTTGATGAGAAGGGCATAATGAGAACGGGTCTTATATCATTT>589
*
*
*
*
*
*
*
*
*
*
6796>GAAAATAATAATTATTACTTTAATGAGAATGGTGAAATGCAATTTGGTTATATAAATATAGAAGATAAGATGTTCTATTTTGGTGAAGATGGTGTCATGC>6895
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
1019>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>1019
590>GAAAATAATAATTATTACTTTAATGAGAATGGTGAAATGCAATTTGGTTATATAAATATAGAAGATAAGATGTTCTATTTTGGTGAAGATGGTGTCATGC>689
*
*
*
*
*
*
*
*
*
*
6896>AGATTGGAGTATTTAATACACCAGATGGATTTAAATACTTTGCACATCAAAATACTTTGGATGAGAATTTTGAGGGAGAATCAATAAACTATACTGGTTG>6995
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
1019>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>1019
690>AGATTGGAGTATTTAATACACCAGATGGATTTAAATACTTTGCACATCAAAATACTTTGGATGAGAATTTTGAGGGAGAATCAATAAACTATACTGGTTG>789
*
*
*
*
*
*
*
*
*
*
6996>GTTAGATTTAGATGAAAAGAGATATTATTTT-ACAGATGAATATATTGCAGCAACTGGTTCAGTTATTATTGATGGTGAGGAGTATTATTTTGATCCTGA>7094
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104

56
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
1019>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>1019
790>GTTAGATTTAGATGAAAAGAGATATTATTTTTACAGATGAATATATTGCAGCAACTGGTTCAGTTATTATTGATGGTGAGGAGTATTATTTTGATCCTGA>889
*
*
*
*
7095>TACAGCTCAATTAGTGATTAGTGAAGggtacc~~~~~~~~~~>7126
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
949>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>949
104<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<104
147<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<147
206<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<206
879>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>879
33<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<33
512>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>512
96<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<96
1019>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>1019
890>TACAGCTCAATTAGTGATTAGTGAAGGGTACCGGCCGCATGC>931

57

APPENDIX II: rTcdB-GTD-NVN Sequence Alignment
rTcdB_GTD_NVN.ape (insert from pBMJ_70402; colony 6) from 295 to 2240
Alignment to
_B03_colony6__M13Reverse_015.seq-- Matches:792; Mismatches:0; Gaps:1154; Unattempted:0
_E02_colony6__B2F_004.seq-- Matches:271; Mismatches:0; Gaps:1675; Unattempted:0
_F02_colony6__B2R_003.seq-- Matches:808; Mismatches:0; Gaps:1138; Unattempted:0
_G02_colony6__B3F_002.seq-- Matches:76; Mismatches:0; Gaps:1870; Unattempted:0

*
*
*
*
*
*
*
*
*
*
295>tgtacaATGAGTTTAGTTAATAGAAAACAGTTAGAAAAAATGGCAAATGTAAGATTTCGTACTCAAGAAGATGAATATGTTGCAATATTGGATGCTTTAG>394
54>TGTACAATGAGTTTAGTTAATAGAAAACAGTTAGAAAAAATGGCAAATGTAAGATTTCGTACTCAAGAAGATGAATATGTTGCAATATTGGATGCTTTAG>153
647>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>647
842<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<842
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72
*
*
*
*
*
*
*
*
*
*
395>AAGAATATCATAATATGTCAGAGAATACTGTAGTCGAAAAATATTTAAAATTAAAAGATATAAATAGTTTAACAGATATTTATATAGATACATATAAAAA>494
154>AAGAATATCATAATATGTCAGAGAATACTGTAGTCGAAAAATATTTAAAATTAAAAGATATAAATAGTTTAACAGATATTTATATAGATACATATAAAAA>253
647>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>647
842<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<842
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
495>ATCTGGTAGAAATAAAGCCTTAAAAAAATTTAAGGAATATCTAGTTACAGAAGTATTAGAGCTAAAGAATAATAATTTAACTCCAGTTGAGAAAAATTTA>594
254>ATCTGGTAGAAATAAAGCCTTAAAAAAATTTAAGGAATATCTAGTTACAGAAGTATTAGAGCTAAAGAATAATAATTTAACTCCAGTTGAGAAAAATTTA>353
647>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>647
842<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<842
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
595>CATTTTGTTTGGATTGGAGGTCAAATAAATGACACTGCTATTAATTATATAAATCAATGGAAAGATGTAAATAGTGATTATAATGTTAATGTTTTTTATG>694
354>CATTTTGTTTGGATTGGAGGTCAAATAAATGACACTGCTATTAATTATATAAATCAATGGAAAGATGTAAATAGTGATTATAATGTTAATGTTTTTTATG>453
647>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>647
842<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<842
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
695>ATAGTAATGCATTTTTGATAAACACATTGAAAAAAACTGTAGTAGAATCAGCAATAAATGATACACTTGAATCATTTAGAGAAAACTTAAATGACCCTAG>794
454>ATAGTAATGCATTTTTGATAAACACATTGAAAAAAACTGTAGTAGAATCAGCAATAAATGATACACTTGAATCATTTAGAGAAAACTTAAATGACCCTAG>553
647>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>647
842<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<842
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
795>ATTTGACTATAATAAATTCTTCAGAAAACGTATGGAAATAATTTATGATAAACAGAAAAATTTCATAAACTACTATAAAGCTCAAAGAGAAGAAAATCCT>894
554>ATTTGACTATAATAAATTCTTCAGAAAACGTATGGAAATAATTTATGATAAACAGAAAAATTTCATAAACTACTATAAAGCTCAAAGAGAAGAAAATCCT>653
647>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>647
842<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<842
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
895>GAACTTATAATTGATGATATTGTAAAGACATATCTTTCAAATGAGTATTCAAAGGAGATAGATGAACTTAATACCTATATTGAAGAATCCTTAAATAAAA>994
654>GAACTTATAATTGATGATATTGTAAAGACATATCTTTCAAATGAGTATTCAAAGGAGATAGATGAACTTAATACCTATATTGAAGAATCCTTAAATAAAA>753
647>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>647
842<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<842
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
995>TTACACAGAATAGTGGAAATGATGTTAGAAACTTTGAAGAATTTAAAAATGGAGAGTCATTCAACTTATATGAACAAGAGTTGGTAGAAAGGTGGAATTT>1094
754>TTACACAGAATAGTGGAAATGATGTTAGAAACTTTGAAGAATTTAAAAATGGAGAGTCATTCAACTTATATGAACAAGAGTTGGTAGAAAGG~~~~~~~~>845
648>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~GTGGAATTT>656
842<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<842
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

58
*
*
*
*
*
*
*
*
*
*
1095>AGCTGCTGCTTCTGACATATTAAGAATATCTGCATTAAAAGAAATTGGTGGTATGTATTTAaATGTTaATATGTTACCAGGAATACAACCAGACTTATTT>1194
845>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>845
657>AGCTGCTGCTTCTGACATATTAAGAATATCTGCATTAAAAGAAATTGGTGGTATGTATTTAAATGTTAATATGTTACCAGGAATACAACCAGACTTATTT>756
842<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<842
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
1195>GAGTCTATAGAGAAACCTAGTTCAGTAACAGTGGATTTTTGGGAAATGACAAAGTTAGAAGCTATAATGAAATACAAAGAATATATACCAGAATATACCT>1294
845>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>845
757>GAGTCTATAGAGAAACCTAGTTCAGTAACAGTGGATTTTTGGGAAATGACAAAGTTAGAAGCTATAATGAAATACAAAGAATATATACCAGAATATACCT>856
842<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<842
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
1295>CAGAACATTTTGACATGTTAGACGAAGAAGTTCAAAGTAGTTTTGAATCTGTTCTAGCTTCTAAGTCAGATAAATCAGAAATATTCTCATCACTTGGTGA>1394
845>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>845
857>CAGAACATTTTGACATGTTAGACGAAGAAGTTCAAAGTAGTTTTGAATCTGTTCTAGCTTCT~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>918
841<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~AAGTCAGATAAATCAGAAATATTCTCATCACTTGGTGA<804
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
1395>TATGGAGGCATCACCACTAGAAGTTAAAATTGCATTTAATAGTAAGGGTATTATAAATCAAGGGCTAATTTCTGTGAAAGACTCATATTGTAGCAATTTA>1494
845>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>845
918>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>918
803<TATGGAGGCATCACCACTAGAAGTTAAAATTGCATTTAATAGTAAGGGTATTATAAATCAAGGGCTAATTTCTGTGAAAGACTCATATTGTAGCAATTTA<704
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
1495>ATAGTAAAACAAATCGAGAATAGATATAAAATATTGAATAATAGTTTAAATCCAGCTATTAGCGAGGATAATGATTTTAATACTACAACGAATACCTTTA>1594
845>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>845
918>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>918
703<ATAGTAAAACAAATCGAGAATAGATATAAAATATTGAATAATAGTTTAAATCCAGCTATTAGCGAGGATAATGATTTTAATACTACAACGAATACCTTTA<604
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
1595>TTGATAGTATAATGGCTGAAGCTAATGCAGATAATGGTAGATTTATGATGGAACTAGGAAAGTATTTAAGAGTTGGTTTCTTCCCAGATGTTAAAACTAC>1694
845>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>845
918>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>918
603<TTGATAGTATAATGGCTGAAGCTAATGCAGATAATGGTAGATTTATGATGGAACTAGGAAAGTATTTAAGAGTTGGTTTCTTCCCAGATGTTAAAACTAC<504
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
1695>TATTAACTTAAGTGGCCCTGAAGCATATGCGGCAGCTTATCAAGATTTATTAATGTTTAAAGAAGGCAGTATGAATATCCATTTGATAGAAGCTGATTTA>1794
845>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>845
918>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>918
503<TATTAACTTAAGTGGCCCTGAAGCATATGCGGCAGCTTATCAAGATTTATTAATGTTTAAAGAAGGCAGTATGAATATCCATTTGATAGAAGCTGATTTA<404
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
1795>AGAAACTTTGAAATCTCTAAAACTAATATTTCTCAATCAACTGAACAAGAAATGGCTAGCTTATGGTCATTTGACGATGCAAGAGCTAAAGCTCAATTTG>1894
845>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>845
918>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>918
403<AGAAACTTTGAAATCTCTAAAACTAATATTTCTCAATCAACTGAACAAGAAATGGCTAGCTTATGGTCATTTGACGATGCAAGAGCTAAAGCTCAATTTG<304
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
1895>AAGAATATAAAAGGAATTATTTTGAAGGTTCTCTTGGTGAAGATGATAATCTTGATTTTTCTCAAAATATAGTAGTTGACAAGGAGTATCTTTTAGAAAA>1994
845>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>845
918>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>918
303<AAGAATATAAAAGGAATTATTTTGAAGGTTCTCTTGGTGAAGATGATAATCTTGATTTTTCTCAAAATATAGTAGTTGACAAGGAGTATCTTTTAGAAAA<204
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

59
*
*
*
*
*
*
*
*
*
*
1995>AATATCTTCATTAGCAAGAAGTTCAGAGAGAGGATATATACACTATATTGTTCAGTTACAAGGAGATAAAATTAGTTATGAAGCAGCATGTAACTTATTT>2094
845>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>845
918>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>918
203<AATATCTTCATTAGCAAGAAGTTCAGAGAGAGGATATATACACTATATTGTTCAGTTACAAGGAGATAAAATTAGTTATGAAGCAGCATGTAACTTATTT<104
72>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>72

*
*
*
*
*
*
*
*
*
*
2095>GCAAAGACTCCTTATGaTAGTGTACTATTTCAGAAAAATATAGAAGATTCAGAAATTGCATATTATTATAATCCTGGAGATGGTGAAATACAAGAAATAG>2194
845>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>845
918>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>918
103<GCAAAGACTCCTTATGATAGTGTACTATTTCAGAAAAATATAGAAGATTCAGAAATTGCATATTATTATA~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<34
73>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ATCCTGGAGATGGTGAAATACAAGAAATAG>102

*
*
*
*
*
2195>ACAAGTATAAAATTCCAAGTATAATTTCTGATAGACCTAAGATTAA>2240
845>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>845
918>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~>918
34<~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~<34
103>ACAAGTATAAAATTCCAAGTATAATTTCTGATAGACCTAAGATTAA>148

60
APPENDIX III: pBMJ Plasmid Constructs

Plasmid Name

Parent Vector

Insert

Size (bp)

Primers
Used c

Restriction
Enzymes Used

Resistance
Marker

pBMJ_130401

pHis1522 a

tcdb-WT b

14458

1&2

BsrG1/Kpn1

Amp (E. coli);
Tet (B. meg)

pBMJ_70401

pCR-XL-TOPO

tcdb-GTD

5902

1&3

BsrG1/BsaB1

Kan

pBMJ_70402

pBMJ_70401 (pCR-XL-TOPO)

tcdb-GTD-NVN

5902

4&5
(SDM)

-

Kan

NOTE: Grey indicates protein expression plasmids. i.e. pANK_80403: created by modifying pWH1520.
b
Isolated from C. difficile genomic DNA (ATTC 9689D-5 DR). cSee Table 2.
a
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ABSTRACT
Clostridium difficile (C. diff) is an anaerobic, spore-forming pathogen responsible
for hospital-acquired C. diff-associated diseases (CDAD) that are extremely common
following patient treatment with broad-spectrum antibiotics. Symptoms of CDAD range
from excessive diarrhea, colonic inflammation, pseudomembranous colitis, and in
extreme cases, death. Although enterotoxins A and B (TcdA and TcdB, respectively) are
the main virulence factors involved and antibiotic-resistant strains are continually
emerging today, antibiotic treatment remains the most common method against CDAD.
The work presented here details a potential anti-toxin therapeutic utilizing an epoxidecontaining peptide (NH2-HQSPGepoxyHHGGGC-CONH2) that covalently crosslinks the
enzymatic domain of TcdA and has shown to inhibit glucosyltransferase activity in a
concentration and time-dependent manner. While further analysis is still needed, antitoxin, peptide-based agents as such show promising potential for an advanced remedy
against CDAD.

